var title_f20_23_20848="Glucagon kit PI";
var content_f20_23_20848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F50427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F50427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Glucagon kit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows a glucagon shot kit. The kit includes a syringe and needle, a small vial of glucagon powder, and a carrying case. The way to give a glucagon shot is:",
"    <br>",
"     <ol>",
"      <li>",
"       Stick the needle into the top of the vial, and inject the fluid in the syringe into the vial of powder.",
"      </li>",
"      <li>",
"       Gently swirl the vial to mix the powder and liquid, until the powder dissolves.",
"      </li>",
"      <li>",
"       Draw up the liquid in the vial into the syringe.",
"      </li>",
"      <li>",
"       Stick the needle into the side of the lower belly or upper leg and inject the liquid.",
"      </li>",
"     </ol>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      &copy; Copyright Eli Lilly and Company. All rights reserved. Used with permission.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20848=[""].join("\n");
var outline_f20_23_20848=null;
var title_f20_23_20849="Patient information: Anal abscess and fistula (The Basics)";
var content_f20_23_20849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17210\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/7/12403\">",
"         Anal abscess and fistula",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Anal abscess and fistula (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/anal-abscess-and-fistula-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H16325786\">",
"      <span class=\"h1\">",
"       What is an anal abscess?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An anal abscess is a pus-filled lump in the anus. It happens when a gland inside the anus gets infected.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16325801\">",
"      <span class=\"h1\">",
"       What is an anal fistula?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An anal fistula is a tunnel that forms between the anal gland and the area where the abscess appears on the skin (",
"      <a class=\"graphic graphic_figure graphicRef53613 \" href=\"UTD.htm?12/7/12403\">",
"       figure 1",
"      </a>",
"      ). &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16325818\">",
"      <span class=\"h1\">",
"       What are the symptoms of an anal abscess?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of an anal abscess include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Severe, constant pain in the anal area",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Feeling sick and tired",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16325835\">",
"      <span class=\"h1\">",
"       What are the symptoms of an anal fistula?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of an anal fistula are the same as the symptoms of an anal abscess. But the pain is not as bad and may happen only during a bowel movement. Other symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Red, itchy skin near the anus",
"       </li>",
"       <li>",
"        Pus draining from the anus",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16325852\">",
"      <span class=\"h1\">",
"       Are there tests for anal abscesses or fistulas?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check for an anal abscess or a fistula, your doctor or nurse will look at your anus and do a &ldquo;digital rectal exam.&rdquo; During a digital rectal exam, your doctor or nurse will put a gloved finger into your anus and rectum to feel for lumps or anything abnormal.",
"     </p>",
"     <p>",
"      He or she might also order an &ldquo;imaging test,&rdquo; such as an MRI or a CT scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16325869\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Some people feel better if they: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take &ldquo;sitz&rdquo; baths &ndash; This is a shallow, warm bath that helps clean and heal the anal area. Take them twice a day for 30 minutes each.",
"       </li>",
"       <li>",
"        Use a hand-held shower to gently spray the anal area",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16325884\">",
"      <span class=\"h1\">",
"       How is an anal abscess treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To treat an abscess, your doctor will cut a small hole to drain out the pus. Often, this can be done in a doctor&rsquo;s office. If you have a large or deep abscess, you might need to be treated in a hospital.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16325899\">",
"      <span class=\"h1\">",
"       How is an anal fistula treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To treat a fistula, your doctor will cut open the tunnel to take out the pus and help it heal. If you have a large or deep fistula, you might need to be treated in a hospital.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/23/20849?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17210 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20849=[""].join("\n");
var outline_f20_23_20849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16325786\">",
"      What is an anal abscess?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16325801\">",
"      What is an anal fistula?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16325818\">",
"      What are the symptoms of an anal abscess?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16325835\">",
"      What are the symptoms of an anal fistula?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16325852\">",
"      Are there tests for anal abscesses or fistulas?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16325869\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16325884\">",
"      How is an anal abscess treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16325899\">",
"      How is an anal fistula treated?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17210\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/7/12403\">",
"      Anal abscess and fistula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_23_20850="TURP scope";
var content_f20_23_20850=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Transurethral resection of the prostate (TURP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A resectoscope loaded with a diathermy loop is introduced into the bladder. Under direct vision, strips of prostatic adenoma are resected one at a time and dropped into the bladder. After the entire adenoma is resected, the prostate chips are evacuated from the bladder and hemostasis is achieved with electrocautery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20850=[""].join("\n");
var outline_f20_23_20850=null;
var title_f20_23_20851="Central breast conserving surgery";
var content_f20_23_20851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Central lumpectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Central breast conserving surgery.",
"    <br>",
"     (A) Parallelogram incision for central mastectomy.",
"     <br>",
"      (B) Completed central mastectomy.",
"      <br>",
"       (C) Closure of central mastectomy using parallelogram incision.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Calhoun KE, Anderson BO. Oncoplastic surgery: Segmental resection for lumpectomies. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams and Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"       </div>",
"       <div class=\"contractual\">",
"        <br/>",
"        <a href=\"file://www.lww.com\">",
"         file://www.lww.com",
"        </a>",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20851=[""].join("\n");
var outline_f20_23_20851=null;
var title_f20_23_20852="Doxepin (topical): Patient drug information";
var content_f20_23_20852=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Doxepin (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/8/14470?source=see_link\">",
"     see \"Doxepin (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/54/14181?source=see_link\">",
"     see \"Doxepin (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8082212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prudoxin&trade;;",
"     </li>",
"     <li>",
"      Zonalon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8082218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zonalon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat itching.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to doxepin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Trouble passing urine, glaucoma, or a recent heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11664 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20852=[""].join("\n");
var outline_f20_23_20852=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082212\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082218\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030986\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030988\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030987\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030992\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030993\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030995\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030990\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030991\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030996\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030997\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/32/44551?source=related_link\">",
"      Doxepin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/8/40069?source=related_link\">",
"      Doxepin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/59/24503?source=related_link\">",
"      Doxepin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/8/14470?source=related_link\">",
"      Doxepin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/54/14181?source=related_link\">",
"      Doxepin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_23_20853="Cutaneous anthrax with lymphangitis";
var content_f20_23_20853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Cutaneous anthrax with lymphangitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Necrotic wound with associated erythema and edema of the right forearm of a patient with cutaneous anthrax.",
"    <br>",
"     (B) Lymphangitis with an associated bulla and serous discharge of the medial right arm of the same patient.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Cinquetti G, Banal F, Dupuy A-L, et al. Three related cases of cutaneous anthrax in France. Medicine 2009; 88:371. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20853=[""].join("\n");
var outline_f20_23_20853=null;
var title_f20_23_20854="RLL atelectasis I";
var content_f20_23_20854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right lower lobe atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atelectasis of the right lower lobe characterized by a triangular opacity in the right lower hemithorax (arrow). It has an oblique sharp border towards the rest of the aerated lung that is formed by the major fissure. The overall volume in the right hemithorax is reduced when compared with the left lung. The right hilum is displaced caudally and is partially obscured by the collapsed lobe. The right cardiac border and the right hemidiaphragm are outlined by the hyperexpanded right middle lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20854=[""].join("\n");
var outline_f20_23_20854=null;
var title_f20_23_20855="Palliative care: Issues specific to geriatric patients";
var content_f20_23_20855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Palliative care: Issues specific to geriatric patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/23/20855/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/23/20855/contributors\">",
"     Lynn Bunch O'Neill, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/23/20855/contributors\">",
"     R Sean Morrison, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/23/20855/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/23/20855/contributors\">",
"     Linda Emanuel, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/23/20855/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/23/20855/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/23/20855/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/23/20855/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative care is an interdisciplinary medical specialty that focuses on preventing and relieving suffering and on supporting the best possible quality of life for patients and their families facing serious illness.&nbsp;The primary tenets of palliative care are symptom management; establishing goals of care that are in keeping with the patient&rsquo;s values and preferences; consistent and sustained communication between the patient and all those involved in his or her care; psychosocial, spiritual, and practical support both to patients and their family caregivers; and coordination across sites of care. Palliative care aims to relieve suffering in all stages of disease and is not limited to end of life care. Within an integrated model of medical care, palliative care is provided at the same time as curative or life-prolonging treatments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While palliative care was once considered to be synonymous with end of life care (which was often delivered in a hospice setting), it is now recognized that palliative care can be appropriately offered to patients at any time along the trajectory of any type of life threatening illness, even concurrent with restorative, life-prolonging therapies.",
"   </p>",
"   <p>",
"    Most serious, chronic illness in the United States, Europe, and other developed countries occurs in those aged 65 years and older. These older individuals often live with and die from chronic illnesses that are preceded by long periods of physical decline and functional impairment. Thus, providing medical care for the elderly often involves medically and ethically complex decision-making, requiring consideration of patients' multiple comorbid conditions, their quality of life, and their wishes regarding treatments.",
"   </p>",
"   <p>",
"    Establishing the goals of care is of the utmost importance when treating older adults with life-limiting illnesses. Depending upon the circumstances, this may be done directly with the patient or may require a surrogate decision-maker.",
"   </p>",
"   <p>",
"    Issues in symptom assessment and management that are primarily applicable to the older adult will be reviewed here. General aspects of palliative care relating to decision-making that are relevant to the geriatric population (eg, advance directives) and issues relevant to assessment and management of symptoms in palliative care patients are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28490?source=see_link\">",
"       \"Overview of comprehensive patient assessment in palliative care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link\">",
"       \"Palliative care: Benefits, services, and models of care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link&amp;anchor=H5#H5\">",
"       \"Ethical issues near the end of life\", section on 'Advance care planning'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link&amp;anchor=H7#H7\">",
"       \"Approach to symptom assessment in palliative care\", section on 'Approach to specific symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=see_link\">",
"       \"Overview of managing common non-pain symptoms in palliative care\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYMPTOM ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the major foci of palliative care is the relief of physical suffering through the identification and treatment of symptoms. The spectrum of symptoms in the elderly differs somewhat from that seen in younger persons. As examples, dementia, delirium, urinary incontinence, and a high propensity for falls are more common in older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite these differences in the elderly, elimination of physical pain remains the most common patient need [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28490?source=see_link\">",
"     \"Overview of comprehensive patient assessment in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link\">",
"     \"Approach to symptom assessment in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In older patients with chronic illnesses, the prevalence of symptoms is high and these are often not recognized. The frequency of symptoms in this population was illustrated by a study of community-dwelling elders age 60 or older with advanced chronic obstructive pulmonary disease (COPD), heart failure (HF), or cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/3\">",
"     3",
"    </a>",
"    ]. Overall, 86 percent reported at least one symptom that was rated as moderate or severe and 69 percent had at least two such symptoms. The most commonly reported symptoms included limited activity (61 percent), fatigue (47 percent), and physical discomfort (38 percent).",
"   </p>",
"   <p>",
"    A comprehensive geriatric assessment is a standard part of the baseline evaluation of an older individual. There are a number of validated instruments for this which can provide valuable information regarding the presence and intensity of a wide variety of symptoms. These include the Edmonton Symptom Assessment Scale (ESAS, (",
"    <a class=\"graphic graphic_figure graphicRef65702 \" href=\"UTD.htm?3/30/3567\">",
"     figure 1",
"    </a>",
"    )), the Memorial Symptom Assessment Scale (MSAS,) (",
"    <a class=\"graphic graphic_figure graphicRef60205 \" href=\"UTD.htm?23/13/23762\">",
"     figure 2",
"    </a>",
"    ), or the Rotterdam Symptom Checklist, among others [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some instruments, such as the MSAS and the Rotterdam Symptom Checklist, may be difficult to administer to older adults because of their length. The ESAS may be particularly useful, because it is shorter than some of the other symptom assessment tools [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/4\">",
"     4",
"    </a>",
"    ]. The original ESAS (",
"    <a class=\"graphic graphic_figure graphicRef65702 \" href=\"UTD.htm?3/30/3567\">",
"     figure 1",
"    </a>",
"    ) included ten domains and this has been supplemented with five additional areas aimed at capturing symptoms commonly present in older adults with advanced chronic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/7\">",
"     7",
"    </a>",
"    ]. These domains are summarized in Table 1 (",
"    <a class=\"graphic graphic_table graphicRef56065 \" href=\"UTD.htm?25/43/26299\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Elderly patients often have significant cognitive, motor, visual, or auditory impairments that must be considered when evaluating the presence and intensity of symptoms, and the assessment method should be modified accordingly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As an example, some older adults may find a three-word descriptor scale (mild, moderate, severe) or a graphic pictorial scale easier to use than a 0 to 10 visual analog scale [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite such difficulties, an assessment can usually be completed in the elderly, as was illustrated in a study in which over 80 percent of individuals were able to complete an assessment using one or another of these approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/11\">",
"     11",
"    </a>",
"    ]. The same assessment scale should be used serially, so that the clinician can assess symptom control over time, set reasonable goals, and foster patient trust [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cognitive impairment can make both the assessment and management of symptoms more difficult. In particular, there are concerns that patients with impaired cognition tend to underreport pain, but a study of 750 nursing home residents found that their self-reports were as valid as those from elderly without cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When elderly patients with mild or moderate dementia report pain, they often cannot recall symptoms from earlier times and may not be able to integrate pain symptoms over time. As a consequence, more frequent assessment is often required to adequately identify and assess the severity of pain in these individuals. Close attention should be paid to mood disturbances, functional decline, and changes in behavior that may be a reflection of increasing or new pain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with severe cognitive impairment who are nonverbal, pain and other symptoms often are difficult to identify and may present as agitation, increased confusion, or decreased mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/13\">",
"     13",
"    </a>",
"    ]. In this situation, the clinician should attempt to assess pain and other symptoms by direct observation and through information from caregivers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/14\">",
"     14",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_algorithm graphicRef66129 \" href=\"UTD.htm?36/54/37728\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56065 \" href=\"UTD.htm?25/43/26299\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58023 \" href=\"UTD.htm?25/6/25708\">",
"     table 2",
"    </a>",
"    ). Evidence of pain-related behaviors may become evident during ambulation, transfers, and personal care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYMPTOM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of symptoms in older individuals follows the same principles as in younger patients. However, the approach may require modification because of comorbidities or physiologic changes associated with aging.",
"   </p>",
"   <p>",
"    Differences in symptom management in elderly versus younger patients have been best studied for persistent chronic pain of both somatic and neuropathic origin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chronic somatic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent pain commonly affects older people, and is most frequently associated with musculoskeletal disorders, such as degenerative spine conditions and arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. As many as 80 percent of older individuals diagnosed with cancer experience pain during the course of their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/17\">",
"     17",
"    </a>",
"    ], and pain as a consequence of cancer treatment is increasingly recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/18\">",
"     18",
"    </a>",
"    ]. The distress of cancer pain creates an obligation for clinicians to provide effective pain management, particularly near the end of life. Unrecognized or undertreated pain in the geriatric population can lead to a number of adverse outcomes, including mood change (depression and anxiety), decreased socialization, sleep and appetite disturbance, gait instability, loss of functional capacity, and greater health care use and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of analgesic medications is the most common strategy in the management of pain in older adults. Physiologic changes (eg, decreased renal or hepatic function and altered body fat distribution) may result in higher serum drug levels in elderly patients given the same dose of a medication as younger individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/19\">",
"     19",
"    </a>",
"    ]. Furthermore, older patients may be more susceptible to adverse events. As a result, lower initial doses are generally recommended.",
"   </p>",
"   <p>",
"    Specific recommendations for initial doses of oral analgesic medicines for the elderly from an American Geriatrics Society panel on the pharmacologic management of persistent pain in older adults are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef83201 \" href=\"UTD.htm?11/8/11407\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/0/30730?source=see_link\">",
"     \"Drug prescribing for older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Choice of the proper analgesic medication should be carefully considered based upon the source and intensity of the pain, the patient's previous responses and reactions to analgesic medications, and baseline organ function.",
"   </p>",
"   <p>",
"    Opioid therapy is the first-line approach for moderate or severe chronic pain that is related to cancer. Despite this, they are underprescribed to older adults with malignant pain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/20,21\">",
"     20,21",
"    </a>",
"    ] . As an example, in a cross-sectional cohort study linking patients 65 and older diagnosed with cancer in Ontario who completed a pain assessment as part of systematic symptom screening with a database of opioid prescriptions, one-third of those who described pain as severe did not receive an opioid prescription between the 30 days prior to assessment of pain to seven days afterward [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Opioids have also been endorsed for persistent nonmalignant pain by major professional pain organizations such as the American Geriatrics Society, American Academy of Pain Management, and American Pain Society. However, among the many barriers to use of opioids in this population are fears of addiction and side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/14\">",
"     14",
"    </a>",
"    ]. Clinicians can help to allay patients' concerns by explaining that while physical dependence is unavoidable with opioid analgesics, addiction is extremely rare in older patients and that side effects can be appropriately controlled. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7077?source=see_link\">",
"     \"Assessment of cancer pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=see_link\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with baseline renal insufficiency, opioids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    are safer than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , which has a toxic metabolite that is renally cleared and can, if it accumulates, cause seizures. Care should be taken to ensure that initial doses are low and that dosing intervals are appropriately increased over what would be considered standard for patients with normal organ function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H19#H19\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Use in renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients are at risk of developing the common side effects of opioids (eg, nausea, constipation, pruritus, sedation, mental cloudiness). In older patients, fecal impaction and urinary retention are more common and a particular concern [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/22\">",
"     22",
"    </a>",
"    ]. Therefore, close attention to the regularity of bowel movements and bladder emptying is recommended, especially in patients who are nonverbal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delirium is a common complication in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Although opioids are often cited as culprits in the development of delirium in older adults, carefully controlled studies have demonstrated that proper pain management actually decreased the incidence of delirium in cognitively intact patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/25\">",
"     25",
"    </a>",
"    ]. This finding can be explained by the fact that uncontrolled pain itself is a risk factor for the development of delirium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While there are no specific studies on dosing adjustments for opioids in the geriatric population, a prudent approach is to start with a low dose, monitor closely, and titrate the dose upward as required. A reasonable approach is to begin with 30 to 50 percent of the recommended starting dose for younger adults. The recommendations for initial doses of opioids and other analgesics by an American Geriatric Society Panel on pharmacologic management of persistent pain are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef83201 \" href=\"UTD.htm?11/8/11407\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific issues related to risk assessment and management and driving while patients are receiving therapy with opioids are addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=see_link&amp;anchor=H5#H5\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'Risk assessment and management for patients receiving opioids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=see_link&amp;anchor=H7613328#H7613328\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'Driving safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neuropathic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathic pain syndromes are common in older adults. Etiologies can include a spectrum of disorders (eg, diabetic neuropathy, post-herpetic neuralgia, spinal stenosis). General aspects of the management of neuropathic pain in cancer patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link&amp;anchor=H18#H18\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for neuropathic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to opioids, a number of pharmacologic agents termed adjuvant analgesics, or coanalgesics may be useful in the treatment of neuropathic pain and have special considerations in the geriatric population.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      is widely used in the treatment of neuropathic pain, but common side effects include somnolence and ataxia, which can be particularly problematic in the geriatric population. If gabapentin is used in older adults, treatment should be initiated with a dose of 100 mg at night (",
"      <a class=\"graphic graphic_table graphicRef83201 \" href=\"UTD.htm?11/8/11407\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/14\">",
"       14",
"      </a>",
"      ]. Patients should be questioned specifically about these side effects before any increases in the dose [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/22\">",
"       22",
"      </a>",
"      ]. Likewise,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      is also becoming used more commonly for the treatment of neuropathic pain. There are no specific dosing adjustments recommended for the geriatric population. With both gabapentin and pregabalin, care should be taken when discontinuing therapy as a withdrawal syndrome can occur. Pregabalin should be tapered off over a week. Gabapentin should be tapered gradually. The length of the gabapentin taper will depend on the maximum dose of gabapentin that a patient is on at the time of the initiation of the taper. (See",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       \"Gabapentin: Drug information\"",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       \"Pregabalin: Drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While both tricyclic antidepressants (TCAs) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      have been shown to be effective in neuropathic pain, their side effects and potential for drug-drug interactions limit their utility in older adults [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/26\">",
"       26",
"      </a>",
"      ]. Other medications that have been evaluated for the treatment of neuropathic pain include the selective serotonin reuptake inhibitors (SSRIs) and mixed reuptake inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ). These agents may be particularly useful in elderly patients because of their favorable side-effect profiles. Recommended initial doses for persistent pain are outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef83201 \" href=\"UTD.htm?11/8/11407\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transdermal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      can be useful in the elderly to treat both neuropathic and localized, nociceptive pain because of its low incidence of side effects. Proper usage of transdermal lidocaine is critical, and careful instructions should be provided. Transdermal lidocaine should be applied for 12 hours and removed for 12 hours each day, and patients can cut the patches in half in order to utilize them on different parts of the body (eg, the right and the left knee) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20855/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link&amp;anchor=H14#H14\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Topical therapies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who are also using other transdermal preparations (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    ) should be carefully instructed regarding the differences between these medications and their appropriate use. While transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    patches can be cut with scissors, the others cannot. Confusion is a particular concern when a patient is using transdermal preparations of both lidocaine and fentanyl for pain management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major depression is a treatable condition, even in terminally ill patients. The more favorable side effect profile of newer antidepressants has facilitated their use in the elderly and medically ill. Because treatment with these agents is relatively benign and well tolerated, clinicians should have a low threshold for initiating therapy. The treatment of depression in palliative care is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link&amp;anchor=H20#H20\">",
"     \"Assessment and management of depression in palliative care\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;While other symptoms including delirium, dyspnea, fatigue, nausea, constipation, and anorexia are all common in older adults, there is a paucity of evidence focusing specifically on their evaluation and management in older adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palliative care utilizes an interdisciplinary team to focus on preventing and relieving suffering, regardless of the disease, stage, or need for other therapies. Although the goals of palliative care in the elderly are the same as those in younger individuals, older persons often live with and die from chronic illnesses that are preceded by long periods of physical decline and functional impairment.",
"     </li>",
"     <li>",
"      Palliative care in the geriatric population requires an accurate identification of all symptoms, and the comprehensive geriatric assessment may be particularly useful for this purpose. Elderly patients often have significant impairments that make such as assessment difficult. Simplified instruments, such as the Edmonton Symptom Assessment Scale, may circumvent these difficulties and are particularly useful. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Symptom assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of symptoms in the older patient follows the same principles as that in younger persons. However, differences in side effect profiles and the metabolic handling of medications in the elderly need to be considered. These factors may influence the choice and dose of medications in the geriatric population. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Symptom management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/1\">",
"      Kapo J, Morrison LJ, Liao S. Palliative care for the older adult. J Palliat Med 2007; 10:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/2\">",
"      Wijk H, Grimby A. Needs of elderly patients in palliative care. Am J Hosp Palliat Care 2008; 25:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/3\">",
"      Walke LM, Gallo WT, Tinetti ME, Fried TR. The burden of symptoms among community-dwelling older persons with advanced chronic disease. Arch Intern Med 2004; 164:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/4\">",
"      Bruera E, Kuehn N, Miller MJ, et al. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991; 7:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/5\">",
"      Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994; 30A:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/6\">",
"      de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/7\">",
"      Walke LM, Byers AL, McCorkle R, Fried TR. Symptom assessment in community-dwelling older adults with advanced chronic disease. J Pain Symptom Manage 2006; 31:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/8\">",
"      Ferrell BA. Pain evaluation and management in the nursing home. Ann Intern Med 1995; 123:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/9\">",
"      Hadjistavropoulos T, Herr K, Turk DC, et al. An interdisciplinary expert consensus statement on assessment of pain in older persons. Clin J Pain 2007; 23:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/10\">",
"      Morrison LJ, Morrison RS. Palliative care and pain management. Med Clin North Am 2006; 90:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/11\">",
"      Ferrell BA, Ferrell BR, Rivera L. Pain in cognitively impaired nursing home patients. J Pain Symptom Manage 1995; 10:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/12\">",
"      Parmelee PA, Smith B, Katz IR. Pain complaints and cognitive status among elderly institution residents. J Am Geriatr Soc 1993; 41:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/13\">",
"      Pautex S, Michon A, Guedira M, et al. Pain in severe dementia: self-assessment or observational scales? J Am Geriatr Soc 2006; 54:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/14\">",
"      American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009; 57:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/15\">",
"      Helme RD, Gibson SJ. The epidemiology of pain in elderly people. Clin Geriatr Med 2001; 17:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/16\">",
"      Thomas E, Peat G, Harris L, et al. The prevalence of pain and pain interference in a general population of older adults: cross-sectional findings from the North Staffordshire Osteoarthritis Project (NorStOP). Pain 2004; 110:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/17\">",
"      Rao A, Cohen HJ. Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monogr 2004; :150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/18\">",
"      Potter J, Higginson IJ. Pain experienced by lung cancer patients: a review of prevalence, causes and pathophysiology. Lung Cancer 2004; 43:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/19\">",
"      Goldstein NE, Morrison RS. Treatment of pain in older patients. Crit Rev Oncol Hematol 2005; 54:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/20\">",
"      Barbera L, Seow H, Husain A, et al. Opioid prescription after pain assessment: a population-based cohort of elderly patients with cancer. J Clin Oncol 2012; 30:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/21\">",
"      Higginson IJ, Gao W. Opioid prescribing for cancer pain during the last 3 months of life: associated factors and 9-year trends in a nationwide United Kingdom cohort study. J Clin Oncol 2012; 30:4373.",
"     </a>",
"    </li>",
"    <li>",
"     Bishop, TF, Morrison, RS. Geriatric palliative care&mdash;Part I: Pain and symptom management. Clinical Geriatrics 2006 (in press).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/23\">",
"      Francis J. Delirium in older patients. J Am Geriatr Soc 1992; 40:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/24\">",
"      Kiely DK, Bergmann MA, Jones RN, et al. Characteristics associated with delirium persistence among newly admitted post-acute facility patients. J Gerontol A Biol Sci Med Sci 2004; 59:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/25\">",
"      Morrison RS, Magaziner J, Gilbert M, et al. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. J Gerontol A Biol Sci Med Sci 2003; 58:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/26\">",
"      Small GW. Tricyclic antidepressants for medically ill geriatric patients. J Clin Psychiatry 1989; 50 Suppl:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20855/abstract/27\">",
"      Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003; 43:111.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2208 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20855=[""].join("\n");
var outline_f20_23_20855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYMPTOM ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYMPTOM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chronic somatic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neuropathic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2208\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2208|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?36/54/37728\" title=\"algorithm 1\">",
"      Assess pain cogn impaired",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2208|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/30/3567\" title=\"figure 1\">",
"      Edmonton symptom assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/13/23762\" title=\"figure 2\">",
"      Memorial symptom assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2208|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/43/26299\" title=\"table 1\">",
"      Domains ESAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/6/25708\" title=\"table 2\">",
"      Common pain behav elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/8/11407\" title=\"table 3\">",
"      Recommended initial doses oral drugs for chronic pain in elderly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=related_link\">",
"      Approach to symptom assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=related_link\">",
"      Assessment and management of depression in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/0/30730?source=related_link\">",
"      Drug prescribing for older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=related_link\">",
"      Gabapentin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28490?source=related_link\">",
"      Overview of comprehensive patient assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=related_link\">",
"      Pregabalin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_23_20856="Technique of axillary lymph node dissection";
var content_f20_23_20856=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Technique of axillary lymph node dissection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/23/20856/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/23/20856/contributors\">",
"     Julie Margenthaler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/23/20856/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/23/20856/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/23/20856/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/23/20856/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/23/20856/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H28306962\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the axilla provides information for treatment decisions in patients with invasive breast cancer. Axillary lymph node dissection is the standard initial approach for breast cancer patients who are clinically node positive. Sentinel node biopsy is the standard initial approach for patients with early stage breast cancer who are clinically node negative.",
"   </p>",
"   <p>",
"    The technique of axillary lymph node dissection (ALND) will be reviewed here. The approach to management of the regional lymph nodes in breast cancer, sentinel node biopsy indications and outcomes, sentinel node biopsy techniques, and the effect of ALND on patient survival are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of the regional lymph nodes in breast cancer\", section on 'Axillary dissection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20296?source=see_link\">",
"     \"Sentinel lymph node biopsy in breast cancer: Techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of the regional lymph nodes in breast cancer\", section on 'Impact of ALND on survival'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28306969\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axillary lymph node dissection (ALND) is indicated for most patients with positive ipsilateral axillary lymph nodes, when diagnosed by sentinel lymph node biopsy or fine needle aspiration. However, the need for ALND in patients with a positive SLNB showing micrometastases or macrometastases in",
"    <strong>",
"     less than three nodes",
"    </strong>",
"    has been questioned and remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/1\">",
"     1",
"    </a>",
"    ]. The management of a positive sentinel lymph node biopsy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of the regional lymph nodes in breast cancer\", section on 'Axillary dissection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link&amp;anchor=H9#H9\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\", section on 'Management of SLN metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with known nodal involvement, staging should be performed to assess the extent of disease. Patients found to have distant metastases usually do not need ALND. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28306984\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALND is contraindicated as a first-line method of axillary staging for patients with early stage breast cancer who are clinically node negative and patients with ductal carcinoma in situ (DCIS). Completion ALND is not recommended in the setting of a negative sentinel lymph node biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link&amp;anchor=H5456194#H5456194\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\", section on 'When should completion axillary dissection be performed?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1540699\">",
"    <span class=\"h1\">",
"     PREOPERATIVE AXILLARY ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with clinically suspicious lymph nodes, a pre-operative axillary ultrasound with fine needle aspiration or core biopsy of suspicious areas provides a means to identify patients who have positive nodes, and thus need ALND rather than a sentinel lymph node biopsy (",
"    <a class=\"graphic graphic_table graphicRef52186 \" href=\"UTD.htm?0/12/203\">",
"     table 1",
"    </a>",
"    ). If the axillary lymph nodes are morphologically normal, or if the cytopathology is negative or nondiagnostic, sentinel lymph node biopsy should be performed (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67261 \" href=\"UTD.htm?15/19/15664\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82343 \" href=\"UTD.htm?43/23/44403\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54435 \" href=\"UTD.htm?25/26/26019\">",
"     image 3",
"    </a>",
"    ). &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link&amp;anchor=H4#H4\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\", section on 'The role of ultrasound in sentinel node evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8369105\">",
"    <span class=\"h1\">",
"     SURGICAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgeon must understand the complex anatomy of the axilla in order to preserve maximum muscular function and sensation (",
"    <a class=\"graphic graphic_figure graphicRef58037 \" href=\"UTD.htm?17/5/17493\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69782 \" href=\"UTD.htm?18/5/18520\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8370030\">",
"    <span class=\"h2\">",
"     Borders of the axilla",
"    </span>",
"    &nbsp;&mdash;&nbsp;The boundaries of the ALND are the axillary vein superiorly, the serratus anterior muscle medially, and the latissimus dorsi muscle laterally (",
"    <a class=\"graphic graphic_figure graphicRef62255 \" href=\"UTD.htm?31/49/32535\">",
"     figure 3",
"    </a>",
"    ). From the anatomic perspective, the axillary space is actually a pyramidal compartment with an apex, base and four walls.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The apex of the axilla is the costoclavicular ligament.",
"     </li>",
"     <li>",
"      The base of the axilla is comprised of skin and axillary fascia.",
"     </li>",
"     <li>",
"      The anterior boundary of the axilla is the pectoralis major and pectoralis minor and subclavius muscles, enclosed in the clavipectoral fascia.",
"     </li>",
"     <li>",
"      The posterior boundary of the axilla is the subscapularis, teres minor, and latissimus dorsi muscles.",
"     </li>",
"     <li>",
"      The lateral wall of the axilla is the narrow space at the bicipital groove on the humerus between the insertions of the muscles of the anterior and posterior walls.",
"     </li>",
"     <li>",
"      The medial border of the axilla is the ribs and intercostal muscles covered with the serratus anterior muscle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5542921\">",
"    <span class=\"h2\">",
"     Contents of the axilla",
"    </span>",
"    &nbsp;&mdash;&nbsp;The axilla contains the blood vessels, lymphatic trunks, and the nerves to the arm. The dissection should be inferior to the axillary vein; thus, the axillary artery and brachial plexus (",
"    <a class=\"graphic graphic_figure graphicRef50576 \" href=\"UTD.htm?34/25/35222\">",
"     figure 4",
"    </a>",
"    ) are superior to the surgical field.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8370037\">",
"    <span class=\"h3\">",
"     Motor nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major motor nerves of the axilla encountered during axillary dissection include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The long thoracic nerve (&ldquo;nerve of Bell&rdquo;) runs parallel to the chest wall and innervates the serratus anterior muscle. If this nerve is injured, the patient will have a protruding &ldquo;winged&rdquo; scapula deformity.",
"     </li>",
"     <li>",
"      The thoracodorsal nerve marks the deep aspect of the axillary space and innervates the latissimus dorsi muscle. &nbsp;Injury to this nerve denervates the latissimus dorsi and leads to weakness of internal rotation and shoulder abduction.",
"     </li>",
"     <li>",
"      The medial and lateral pectoral nerves innervate the pectoralis minor and major muscles. Injury to these nerves leads to denervation atrophy and shortening of the pectoral muscles with limitation of shoulder mobility and compromise of the cosmetic result.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8370044\">",
"    <span class=\"h3\">",
"     Sensory nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intercostobrachial nerves are sensory nerves that traverse the axilla to supply the skin on the medial and posterior arm, axilla, and posterior axillary line. The intercostobrachial nerves exit the fascia of the chest wall at the second and third intercostal spaces. The highest intercostal brachial nerves supply sensation to the upper medial arm and the patient will have diminished sensation or hyperesthesias if these nerves are injured. The lower intercostal nerves supply skin sensation to the axilla and are rarely saved, since they course through the specimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8370051\">",
"    <span class=\"h3\">",
"     Lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The axillary lymph nodes are divided into three levels based upon their relationship to the pectoralis minor muscle (",
"    <a class=\"graphic graphic_figure graphicRef74746 \" href=\"UTD.htm?8/34/8744\">",
"     figure 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Level I: Inferior and lateral to the pectoralis minor muscle",
"     </li>",
"     <li>",
"      Level II: Posterior to the pectoralis minor and below the axillary vein",
"     </li>",
"     <li>",
"      Level III (infraclavicular): Medial to the pectoralis minor and against the chest wall; involvement of these nodes alters nodal staging classification due to their poor prognostic significance. Level III lymph node involvement automatically confers a pN3 status (",
"      <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24278?source=see_link\">",
"       \"Tumor node metastasis (TNM) staging classification for breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H815960\">",
"    <span class=\"h3\">",
"     Blood vessels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The axillary artery and vein are enclosed within the axillary sheath with the brachial plexus (",
"    <a class=\"graphic graphic_figure graphicRef61941 \" href=\"UTD.htm?15/43/16053\">",
"     figure 6",
"    </a>",
"    ). The thoracodorsal artery and vein travel with the thoracodorsal nerve and should be preserved (",
"    <a class=\"graphic graphic_figure graphicRef78501 \" href=\"UTD.htm?9/6/9315\">",
"     figure 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H815739\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Operating room safety",
"      </strong>",
"      &mdash; Operating room safety, including obtaining informed consent and site marking, are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33369?source=see_link\">",
"       \"Operating room safety\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Anesthesia &mdash;",
"      </strong>",
"      ALND is performed under general anesthesia. The patient should",
"      <strong>",
"       not",
"      </strong>",
"      be paralyzed so that testing of the large motor nerves during dissection is possible.",
"     </li>",
"     <li>",
"      <strong>",
"       Antibiotics &mdash;",
"      </strong>",
"      A preoperative antibiotic, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      , should be administered after arriving in the operating room and before the incision is made [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. The efficacy of antibiotic prophylaxis decreases if administered more than one hour before surgery (",
"      <a class=\"graphic graphic_table graphicRef79097 \" href=\"UTD.htm?22/46/23275\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/9-11\">",
"       9-11",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A meta-analysis of the randomized controlled trials of preoperative antibiotics versus placebo in patients undergoing breast surgery found that the use of preoperative antibiotics was associated with a significant reduction in infection (relative risk = 0.60; CI = 0.45 to 0.81) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"       \"Overview of control measures to prevent surgical site infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Deep venous thrombosis prophylaxis &mdash;",
"      </strong>",
"      For patients undergoing general anesthesia, primary prophylaxis for prevention of deep venous thrombosis, such as sequential compression devices, should be employed (",
"      <a class=\"graphic graphic_table graphicRef50947 \" href=\"UTD.htm?34/54/35693\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28307036\">",
"    <span class=\"h1\">",
"     SURGICAL TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An axillary lymph node dissection (ALND) is usually performed through a small incision and confirmation of the anatomic landmarks is crucial for avoiding injuries with functional consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"local\" href=\"#H8369105\">",
"     'Surgical anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H816049\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient positioning should allow maximum exposure of the axilla. The patient is positioned supine with her arms extended on arm boards at &le;90 degrees abduction from the chest wall. Arm positioning with &gt;90 degrees of abduction from the chest wall increases the potential for stretching the brachial plexus and should be avoided. It is important to position the arm while the patient is awake to make sure the arm is not abducted beyond what is comfortable for the patient, especially if there are preexisting problems with shoulder mobility.",
"   </p>",
"   <p>",
"    The ipsilateral arm can be included in the prepped field at the discretion of the surgeon, allowing the arm to be mobilized during the procedure. The lateral chest wall should be positioned along the edge of the operating table. After the patient is securely belted, the table can be tilted with the operative side up to allow optimal visualization of the axilla.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H816057\">",
"    <span class=\"h2\">",
"     Incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALND may be performed within the context of a modified radical mastectomy for patients requiring complete removal of the breast, in combination with a partial mastectomy for breast conservation, or as a separate procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"     \"Breast conserving therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link\">",
"     \"Mastectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incision will vary depending upon the breast surgery being performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients undergoing ALND alone or concurrently with partial mastectomy, a curvilinear incision is made approximately 1 to 2 cm below the edge of the axillary hair line following the natural skin folds (Langer&rsquo;s lines), extending from the anterior to the posterior axillary fold (",
"      <a class=\"graphic graphic_figure graphicRef52834 \" href=\"UTD.htm?6/16/6402\">",
"       figure 8",
"      </a>",
"      ). A better cosmetic result is obtained if the incision does not cross the anterior or posterior axillary folds.",
"     </li>",
"     <li>",
"      For patients undergoing standard modified radical mastectomy without reconstruction, the ALND can be performed through the mastectomy incision once the breast has been removed.",
"     </li>",
"     <li>",
"      For patients undergoing a skin-sparing modified radical mastectomy with immediate reconstruction, the skin opening can be positioned over the axilla once the breast is removed to allow for the ALND. A small radial skin incision can be extended laterally to facilitate this approach. Alternatively, a separate incision in the axilla can be used when it is not feasible to reach the axilla through the breast skin opening.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H816102\">",
"    <span class=\"h2\">",
"     Critical steps of the dissection",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Definition of pectoralis muscles",
"      </strong>",
"       The lateral edge of the pectoralis major muscle is retracted medially to expose the pectoralis minor muscle and allow interpectoral dissection of Rotter&rsquo;s lymph nodes. The medial pectoral neurovascular bundle, which innervates the pectoralis major and minor muscles, should be preserved during the dissection. The neurovascular bundle passes through the pectoralis minor muscle in 60 percent of patients, and passes laterally around the pectoralis minor muscle in 40 percent.",
"     </li>",
"     <li>",
"      <strong>",
"       Identification of latissimus dorsi ",
"      </strong>",
"      The anterior surface of the latissimus dorsi muscle is the lateral border of the axillary dissection (",
"      <a class=\"graphic graphic_figure graphicRef64682 \" href=\"UTD.htm?38/50/39717\">",
"       figure 9",
"      </a>",
"      ). Dissection along the latissimus dorsi border is extended inferiorly until the muscle begins to pull toward the chest wall and superiorly to the tendon of insertion.",
"     </li>",
"     <li>",
"      <strong>",
"       Clavipectoral fascia ",
"      </strong>",
"      The clavipectoral fascia is divided at the level of the inferior axillary sheath to expose the underlying fat pad and axillary lymph nodes within the fat.",
"     </li>",
"     <li>",
"      <strong>",
"       Axillary vein",
"      </strong>",
"       Dissection is carried posteriorly until the axillary vein is visualized, with care not to open the axillary sheath and strip or skeletonize the vein unless there is extensive nodal disease, because this increases the risk of injury to the vessels and lymphatics, which can increase the risk of lymphedema [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/3\">",
"       3",
"      </a>",
"      ]. The axillary vein often bifurcates or trifurcates within the axillary space. Thus, transverse venous structures high in the axilla should",
"      <strong>",
"       never",
"      </strong>",
"      be ligated, even when they appear smaller than that expected for an axillary vein.",
"     </li>",
"     <li>",
"      <strong>",
"       Mobilization of the axillary fat pad ",
"      </strong>",
"      The fatty tissue and nodes are dissected off the chest wall and the inferior surface of the axillary vein.",
"     </li>",
"     <li>",
"      <strong>",
"       Identification of intercostobrachial nerves ",
"      </strong>",
"      The sensory intercostobrachial nerves are encountered during the lateral dissection along the latissimus dorsi. It is difficult to spare branches that are located far inferior to the axillary vein, but this can be accomplished with careful dissection. By sharp dissection, the adventitial tissues can be incised along the nerve so that the nerve can be retracted anteriorly away from the underlying axillary fat pad and contents. If the intercostobrachial nerve branches cannot be spared, ligation should be performed sharply to avoid electrocautery conduction injury.",
"     </li>",
"     <li>",
"      <strong>",
"       Identification of motor nerves ",
"      </strong>",
"      The positions of the long thoracic nerve and thoracodorsal neurovascular bundle can vary slightly from patient to patient. The best approach is to preserve all neural and vascular structures in unexpected positions, until the full axillary anatomy can be determined and before anything critical is sacrificed.",
"      <br/>",
"      <br/>",
"      The long thoracic nerve is identified by blunt dissection just below the medial aspect of the axillary vein and just lateral to the chest wall. One can often feel the nerve prior to visualizing it by palpating the tissues along the chest wall (",
"      <a class=\"graphic graphic_figure graphicRef53451 \" href=\"UTD.htm?34/43/35506\">",
"       figure 10",
"      </a>",
"      ). Once the nerve is identified, the plane is extended inferiorly for the length of the axillary field. It is important to try to keep the long thoracic nerve against the chest wall to reduce the likelihood of injury. The fascial layer on the serratus anterior that holds the long thoracic nerve in place should",
"      <strong>",
"       not",
"      </strong>",
"      be breached to avoid injury to the nerve.",
"      <br/>",
"      <br/>",
"      The thoracodorsal neurovascular bundle can be identified by dissecting in the mid-axilla just inferior to the axillary vein (",
"      <a class=\"graphic graphic_figure graphicRef78501 \" href=\"UTD.htm?9/6/9315\">",
"       figure 7",
"      </a>",
"      ). There is often a large superficial venous tributary arising from the axillary vein, called the thoracoepigastric vein, which is often just anterior to the position of the thoracodorsal neurovascular bundle. This superficial vein should not be transected until the neurovascular bundle is confirmed.",
"     </li>",
"     <li>",
"      <strong>",
"       Extent of dissection ",
"      </strong>",
"      The",
"      <strong>",
"      </strong>",
"      extent of dissection is defined by anatomic location (",
"      <a class=\"graphic graphic_figure graphicRef57770 \" href=\"UTD.htm?39/39/40563\">",
"       figure 11",
"      </a>",
"      ). An accurate determination of the nodal level of a resected specimen can only be made if the specimen is marked by the surgeon or separated into levels before it is evaluated by the pathologist. (See",
"      <a class=\"local\" href=\"#H8369105\">",
"       'Surgical anatomy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The extent of dissection is a tradeoff between the greater morbidity of a more extensive ALND and the possibility of leaving residual untreated axillary disease. In general, a level I and II anatomic ALND is the preferred procedure for axillary assessment [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/13\">",
"       13",
"      </a>",
"      ]. The typical level",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      dissection should yield &ge;10 axillary lymph nodes, although the range is highly variable. (See",
"      <a class=\"local\" href=\"#H8370051\">",
"       'Lymph nodes'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Routine removal of level III nodes is unnecessary for staging but should be carried out to maximize local control if grossly positive axillary lymph nodes are identified intraoperatively. Level III lymph node dissection significantly increases the morbidity of the ALND. This level is not generally formally dissected; clinically suspicious level III nodes are separately resected and labeled as such for the pathologist. The reported incidence of skip metastases in the level III nodes with uninvolved level I nodes ranges from 0.2 to 3.1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/14-19\">",
"       14-19",
"      </a>",
"      ]. These numbers correlate well with locoregional recurrence rates following a level I and II ALND in women undergoing breast conserving surgery (3 percent or less) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/20-24\">",
"       20-24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"       \"Breast conserving therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Completion of dissection &minus;",
"      </strong>",
"      Once the long thoracic and thoracodorsal nerves have been identified, the axillary contents can be removed from the defined boundaries. Blunt dissection is used to define the tissue planes between the axillary fat pad and contents and the underlying structures, progressing from superior to inferior in the operative field (",
"      <a class=\"graphic graphic_figure graphicRef63143 \" href=\"UTD.htm?25/56/26498\">",
"       figure 12",
"      </a>",
"      ). Palpation of level III nodes can then be performed by running the ventral surface of the index finger behind the pectoralis minor muscle and toward the infraclavicular space. If clinically suspicious nodes are palpated, they can be separately resected by retracting the pectoralis minor muscle for exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H816085\">",
"    <span class=\"h2\">",
"     Drains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before closure, some surgeons place a closed suction drain in the axillary space through a separate stab wound in the low axilla above the bra line. Other surgeons prefer not to place a drain; they aspirate any seroma that develops in the postoperative period, which is more",
"    <strong>",
"    </strong>",
"    comfortable for the patient and allows discharge after surgery without a hospital stay or cumbersome drain care [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/25\">",
"     25",
"    </a>",
"    ]. Meta-analyses of available randomized trials have demonstrated that axillary drains decrease seroma formation and the volume and frequency of postoperative seroma aspiration; however, they extend hospital stay and do not affect the incidence of wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4692244\">",
"    <span class=\"h2\">",
"     Axillary reverse mapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axillary reverse mapping (ARM) is an experimental technique, being investigated as a method of preserving the upper extremity lymphatics during ALND in an attempt to reduce the risk of postoperative lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Blue dye is injected in the upper inner ipsilateral arm and blue lymphatics and nodes are avoided during ALND. In two studies of 23 patients each, metastases were present in the nodes related to ARM sampling in 14 and 60 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. Thus, further studies are needed to determine the long-term oncologic outcomes of this novel technique, which should not be used outside of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28307073\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain control is achieved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or a short course of narcotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a drain was used, the patient is instructed on the care of the axillary drain and asked to keep a daily log of the drainage volume. The drain can be removed when the output is 30 mL or less a day. Activity restrictions include avoidance of submersion of the incision in water and avoidance of driving, strenuous activity, or heavy lifting while the drain is in place. After drain removal, patients are encouraged to gradually increase their level of activity and range of motion.",
"   </p>",
"   <p>",
"    If a drain was not used, the patient should be evaluated for seroma formation a week after surgery. If the seroma is large or symptomatic it should be aspirated. A small seroma will usually respond to conservative care with rest, arm elevation, and icing of the axilla.",
"   </p>",
"   <p>",
"    Simple range of motion exercises will enable most patients to resume full activity. Some patients may require physical therapy to regain full range of motion. Patients should receive instruction in the prevention and recognition of lymphedema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=see_link\">",
"     \"Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28307087\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomic disruption caused by ALND may result in lymphedema, nerve injury, and shoulder dysfunction, which compromise functionality and quality of life.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Infection",
"      </strong>",
"      &mdash; The incidence of postoperative wound infection following axillary dissection varies from 3 to 15 percent in the literature, though it is difficult to assess the contribution of ALND in the setting of a combined breast surgical procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/31-34\">",
"       31-34",
"      </a>",
"      ]. The most common organisms are usually gram positive (streptococcal or staphylococcal species) and will respond to treatment with appropriate oral antibiotics. If there is an underlying seroma, it should be aspirated and cultured to direct antibiotic treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36406?source=see_link\">",
"       \"Epidemiology and pathogenesis of and risk factors for surgical site infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hematoma",
"      </strong>",
"      &mdash; The reported incidence of postoperative hematoma has varied from 2 to 10 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/31,32,35\">",
"       31,32,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Seroma",
"      </strong>",
"      &mdash; The normal lymphatic drainage of the breast to the axilla can lead to seroma formation after axillary dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/35\">",
"       35",
"      </a>",
"      ]. Seromas can be diminished with the use of drains or managed via percutaneous aspiration [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H816085\">",
"       'Drains'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Arm morbidity",
"      </strong>",
"      &mdash; Lymphedema of the arm is a potential and serious complication of ALND. The rate varies substantially with the level of dissection and whether or not postoperative radiation therapy is used. Issues related to lymphedema are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"       \"Clinical manifestations and diagnosis of lymphedema\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"       \"Prevention and treatment of lymphedema\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=see_link\">",
"       \"Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Shoulder stiffness, and numbness and paresthesias in the upper arm are common complaints following ALND; although they do not usually interfere with daily living, they may reduce the quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/37-41\">",
"       37-41",
"      </a>",
"      ]. &nbsp;In one series, 42 percent of women had subjective or objective arm impairment (eg, pain, reduced grip strength) one year after ALND [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20856/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Nerve injury",
"      </strong>",
"      &mdash; The risk of major motor nerve injury following ALND is &lt;1 percent. Injury to the",
"      <strong>",
"      </strong>",
"      long thoracic nerve results in a winged scapula. Injury to the thoracodorsal nerve weakens shoulder abduction and internal rotation. Injury to the medial pectoral nerve may lead to atrophy of the lateral aspect of the pectoralis major muscle, which may impact the overall cosmetic result. Transection of the intercostobrachial nerve results in numbness and paresthesias on the inner upper arm. (See",
"      <a class=\"local\" href=\"#H8370037\">",
"       'Motor nerves'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3690?source=see_link\">",
"       \"Various rehabilitation issues in patients treated for cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28307101\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation of the axilla provides information for treatment decisions in patients with invasive breast cancer. Axillary lymph node dissection (ALND) is the standard initial approach for breast cancer patients who are clinically node positive. Sentinel node biopsy is the standard initial approach for patients with early stage breast cancer who are clinically node negative. (See",
"      <a class=\"local\" href=\"#H28306962\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ALND is indicated for most patients with known positive ipsilateral axillary lymph nodes diagnosed either by sentinel lymph node biopsy or fine needle aspiration. However, the need for ALND in patients with a positive SLNB showing micrometastases or macrometastases in",
"      <strong>",
"       less than three nodes",
"      </strong>",
"      has been questioned and remains controversial. (See",
"      <a class=\"local\" href=\"#H28306969\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ALND is contraindicated as a first-line method of axillary staging for patients with early stage breast cancer who are clinically node negative and patients with ductal carcinoma in situ (DCIS). Completion ALND is not recommended in the setting of a negative sentinel lymph node biopsy. (See",
"      <a class=\"local\" href=\"#H28306984\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with clinically suspicious lymph nodes, preoperative axillary ultrasound with fine needle aspiration or core biopsy of suspicious areas provides a means to identify patients who have positive nodes, and thus need ALND rather than a sentinel lymph node biopsy. If the axillary lymph nodes are morphologically normal, or if the cytopathology is negative or nondiagnostic, a sentinel lymph node biopsy should be performed. (See",
"      <a class=\"local\" href=\"#H1540699\">",
"       'Preoperative axillary ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The surgeon must understand the complex anatomy of the axilla in order to preserve maximum muscular function and sensation. (See",
"      <a class=\"local\" href=\"#H8369105\">",
"       'Surgical anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <strong>",
"      </strong>",
"      level of ALND is defined by anatomic location. Axillary lymph nodes are divided into three levels based upon their relationship to the pectoralis minor muscle. (See",
"      <a class=\"local\" href=\"#H8370051\">",
"       'Lymph nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ALND is usually performed through a small incision and confirmation of the anatomic landmarks is crucial for avoiding injuries with functional consequences. (See",
"      <a class=\"local\" href=\"#H28307036\">",
"       'Surgical technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The anatomic disruption caused by ALND may result in lymphedema, nerve injury, and shoulder dysfunction, which compromise functionality and quality of life. (See",
"      <a class=\"local\" href=\"#H28307087\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/1\">",
"      Carlson GW, Wood WC. Management of axillary lymph node metastasis in breast cancer: making progress. JAMA 2011; 305:606.",
"     </a>",
"    </li>",
"    <li>",
"     Anson, BJ, McVay, CB. Thoracic walls: Breast or mammary region. In: Surgical Anatomy, 6th edition, Anson, BJ, McVay, CB (Eds), Saunders, Philadelphia 1984. p.357.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/3\">",
"      Petrek JA, Blackwood MM. Axillary dissection: current practice and technique. Curr Probl Surg 1995; 32:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/4\">",
"      Ung O, Tan M, Chua B, Barraclough B. Complete axillary dissection: a technique that still has relevance in contemporary management of breast cancer. ANZ J Surg 2006; 76:518.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 6th ed, Greene FL, Page DL, Fleming ID, et al (Eds), Springer-Verlag, New York 2002. p.223.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/6\">",
"      Leaper DJ, Melling AG. Antibiotic prophylaxis in clean surgery: clean non-implant wounds. J Chemother 2001; 13 Spec No 1:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/7\">",
"      Gagliardi AR, Fenech D, Eskicioglu C, et al. Factors influencing antibiotic prophylaxis for surgical site infection prevention in general surgery: a review of the literature. Can J Surg 2009; 52:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/8\">",
"      Throckmorton AD, Boughey JC, Boostrom SY, et al. Postoperative prophylactic antibiotics and surgical site infection rates in breast surgery patients. Ann Surg Oncol 2009; 16:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/9\">",
"      Fry DE. Surgical site infections and the surgical care improvement project (SCIP): evolution of national quality measures. Surg Infect (Larchmt) 2008; 9:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/10\">",
"      Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/11\">",
"      Braxton CC, Gerstenberger PA, Cox GG. Improving antibiotic stewardship: order set implementation to improve prophylactic antimicrobial prescribing in the outpatient surgical setting. J Ambul Care Manage 2010; 33:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/12\">",
"      Tejirian T, DiFronzo LA, Haigh PI. Antibiotic prophylaxis for preventing wound infection after breast surgery: a systematic review and metaanalysis. J Am Coll Surg 2006; 203:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/13\">",
"      NIH consensus conference. Treatment of early-stage breast cancer. JAMA 1991; 265:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/14\">",
"      Chevinsky AH, Ferrara J, James AG, et al. Prospective evaluation of clinical and pathologic detection of axillary metastases in patients with carcinoma of the breast. Surgery 1990; 108:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/15\">",
"      Danforth DN Jr, Findlay PA, McDonald HD, et al. Complete axillary lymph node dissection for stage I-II carcinoma of the breast. J Clin Oncol 1986; 4:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/16\">",
"      Veronesi U, Rilke F, Luini A, et al. Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer 1987; 59:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/17\">",
"      Pigott J, Nichols R, Maddox WA, Balch CM. Metastases to the upper levels of the axillary nodes in carcinoma of the breast and its implications for nodal sampling procedures. Surg Gynecol Obstet 1984; 158:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/18\">",
"      Boova RS, Bonanni R, Rosato FE. Patterns of axillary nodal involvement in breast cancer. Predictability of level one dissection. Ann Surg 1982; 196:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/19\">",
"      Rosen PP, Lesser ML, Kinne DW, Beattie EJ. Discontinuous or \"skip\" metastases in breast carcinoma. Analysis of 1228 axillary dissections. Ann Surg 1983; 197:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/20\">",
"      Siegel BM, Mayzel KA, Love SM. Level I and II axillary dissection in the treatment of early-stage breast cancer. An analysis of 259 consecutive patients. Arch Surg 1990; 125:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/21\">",
"      Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992; 28A:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/22\">",
"      Fowble B, Solin LJ, Schultz DJ, Goodman RL. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys 1989; 17:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/23\">",
"      Halverson KJ, Taylor ME, Perez CA, et al. Regional nodal management and patterns of failure following conservative surgery and radiation therapy for stage I and II breast cancer. Int J Radiat Oncol Biol Phys 1993; 26:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/24\">",
"      Recht A, Pierce SM, Abner A, et al. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol 1991; 9:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/25\">",
"      Jeffrey SS, Goodson WH 3rd, Ikeda DM, et al. Axillary lymphadenectomy for breast cancer without axillary drainage. Arch Surg 1995; 130:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/26\">",
"      Droeser RA, Frey DM, Oertli D, et al. Volume-controlled vs no/short-term drainage after axillary lymph node dissection in breast cancer surgery: a meta-analysis. Breast 2009; 18:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/27\">",
"      He XD, Guo ZH, Tian JH, et al. Whether drainage should be used after surgery for breast cancer? A systematic review of randomized controlled trials. Med Oncol 2011; 28 Suppl 1:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/28\">",
"      Nos C, Kaufmann G, Clough KB, et al. Combined axillary reverse mapping (ARM) technique for breast cancer patients requiring axillary dissection. Ann Surg Oncol 2008; 15:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/29\">",
"      Thompson M, Korourian S, Henry-Tillman R, et al. Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation. Ann Surg Oncol 2007; 14:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/30\">",
"      Bedrosian I, Babiera GV, Mittendorf EA, et al. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer 2010; 116:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/31\">",
"      Crane-Okada R, Wascher RA, Elashoff D, Giuliano AE. Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer. Ann Surg Oncol 2008; 15:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/32\">",
"      Langer I, Guller U, Berclaz G, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg 2007; 245:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/33\">",
"      Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006; 98:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/34\">",
"      Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007; 25:3657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/35\">",
"      Vitug AF, Newman LA. Complications in breast surgery. Surg Clin North Am 2007; 87:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/36\">",
"      Pogson CJ, Adwani A, Ebbs SR. Seroma following breast cancer surgery. Eur J Surg Oncol 2003; 29:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/37\">",
"      Kwan W, Jackson J, Weir LM, et al. Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol 2002; 20:4242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/38\">",
"      Ivens D, Hoe AL, Podd TJ, et al. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992; 66:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/39\">",
"      Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993; 11:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/40\">",
"      Hladiuk M, Huchcroft S, Temple W, Schnurr BE. Arm function after axillary dissection for breast cancer: a pilot study to provide parameter estimates. J Surg Oncol 1992; 50:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20856/abstract/41\">",
"      Keramopoulos A, Tsionou C, Minaretzis D, et al. Arm morbidity following treatment of breast cancer with total axillary dissection: a multivariated approach. Oncology 1993; 50:445.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14984 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20856=[""].join("\n");
var outline_f20_23_20856=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28307101\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28306962\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28306969\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28306984\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1540699\">",
"      PREOPERATIVE AXILLARY ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8369105\">",
"      SURGICAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8370030\">",
"      Borders of the axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5542921\">",
"      Contents of the axilla",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8370037\">",
"      - Motor nerves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8370044\">",
"      - Sensory nerves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8370051\">",
"      - Lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H815960\">",
"      - Blood vessels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H815739\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28307036\">",
"      SURGICAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H816049\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H816057\">",
"      Incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H816102\">",
"      Critical steps of the dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H816085\">",
"      Drains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4692244\">",
"      Axillary reverse mapping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28307073\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28307087\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28307101\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14984\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14984|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/19/15664\" title=\"diagnostic image 1\">",
"      Ultrasound image of normal axillary lymph node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/23/44403\" title=\"diagnostic image 2\">",
"      Ultrasound image of abnormal axillary lymph node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/26/26019\" title=\"diagnostic image 3\">",
"      Ultraound image of Doppler flow in abnormal axillary lymph node",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14984|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/5/17493\" title=\"figure 1\">",
"      Superficial anatomy of the axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/5/18520\" title=\"figure 2\">",
"      Structures of the axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/49/32535\" title=\"figure 3\">",
"      Anatomic boundaries of axillary lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/25/35222\" title=\"figure 4\">",
"      Trunks and cords of the brachial plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/34/8744\" title=\"figure 5\">",
"      Lymphatic drainage of the breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/43/16053\" title=\"figure 6\">",
"      Deep veins of the upper extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/6/9315\" title=\"figure 7\">",
"      Identification of the thoracodorsal bundle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/16/6402\" title=\"figure 8\">",
"      Incision for axillary dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/50/39717\" title=\"figure 9\">",
"      Dissection along the latissimus dorsi muscle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/43/35506\" title=\"figure 10\">",
"      Identification of the long thoracic nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/39/40563\" title=\"figure 11\">",
"      Schematic of the breast and regional lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/56/26498\" title=\"figure 12\">",
"      Completed axillary dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14984|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/12/203\" title=\"table 1\">",
"      US features suspic axillary LN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29920\" title=\"table 2\">",
"      TNM stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/46/23275\" title=\"table 3\">",
"      Timing of surgical prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/54/35693\" title=\"table 4\">",
"      Perioperative VTE prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36406?source=related_link\">",
"      Epidemiology and pathogenesis of and risk factors for surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=related_link\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33369?source=related_link\">",
"      Operating room safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=related_link\">",
"      Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20296?source=related_link\">",
"      Sentinel lymph node biopsy in breast cancer: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24278?source=related_link\">",
"      Tumor node metastasis (TNM) staging classification for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3690?source=related_link\">",
"      Various rehabilitation issues in patients treated for cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_23_20857="Oral lichen planus histopathology";
var content_f20_23_20857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Oral lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parakeratosis, apoptotic keratinocytes, subepithelial clefting, and a lichenoid lymphocytic infiltrate are present in this specimen of oral lichen planus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Bethanee Schlosser.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20857=[""].join("\n");
var outline_f20_23_20857=null;
var title_f20_23_20858="Protection against malaria in the hemoglobinopathies";
var content_f20_23_20858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Protection against malaria in the hemoglobinopathies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/23/20858/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/23/20858/contributors\">",
"     David J Roberts, MA, MB, D. Phil",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/23/20858/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/23/20858/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/23/20858/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/23/20858/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/23/20858/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/23/20858/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/23/20858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history of genetics and the study of malaria are inextricably linked. The burden of disease due to malaria across much of the world has selected for a series of very visible traits of major medical importance, including the alleles of genes encoding hemoglobin, red cell enzymes, and membrane proteins. Furthermore, as might be expected from the intricate life cycle of the parasite in the human host, it now appears that many other genes may also influence the outcome of infection, including some that modulate the immune responses and others that encode for endothelial proteins.",
"   </p>",
"   <p>",
"    The genetic resistance to malarial infection, particularly falciparum malaria, associated with the hemoglobinopathies, will be reviewed here. Resistance associated with abnormalities in red cell surface antigens or cytoskeleton is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=see_link\">",
"     \"Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REVIEW OF MALARIAL INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmodium falciparum malaria, the deadly form of malaria, has a life cycle that includes alternating hosts: a sexual cycle in the insect vector (a female) Anopheles mosquito and a human cycle that includes a liver stage and an erythrocytic stage. Genetic resistance to the blood stage has been extensively documented, but the association of HLA Class I allotypes with protection from malaria suggests genetic traits resistance also during the hepatic stage of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic resistance to P. falciparum malaria at the erythrocytic stage may involve one or more of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inhibition of merozoite entry into the red cell [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Impairment in intracellular growth of the parasite",
"     </li>",
"     <li>",
"      Prevention of the erythrocyte lysis that occurs at the end of parasite maturation, which leads to release of merozoites into the bloodstream",
"     </li>",
"     <li>",
"      Enhanced phagocytosis of parasite-infected red cells [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/4-7\">",
"       4-7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced cytoadherence of infected erythrocytes to endothelial cells, uninfected red blood cells, platelets or antigen-presenting cells.",
"     </li>",
"     <li>",
"      Enhanced immune responses to malarial infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic resistance at the erythrocytic stage has led to the selection of red cell genetic defects at gene frequencies (greater than 1 percent) that imply positive selective pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These defects include hemoglobinopathies (eg, hemoglobins S, C, E, and thalassemia), erythrocyte membrane defects (eg, Southeast Asian ovalocytosis and some forms of elliptocytosis), and metabolic abnormalities (eg, glucose-6-phosphate dehydrogenase deficiency).",
"   </p>",
"   <p>",
"    Although all of the four common types of human malaria (P. falciparum, ovale, vivax, and malariae) can cause selective pressure on the human population, and although P. vivax does cause severe disease and may also indirectly contribute to morbidity and mortality, this effect is most obvious with P. falciparum infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39959?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis of malaria\", section on 'Genetic factors'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MALARIA PROTECTION AND INHERITED FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first observations suggesting that malaria is influenced by inherited factors were made in the study of malaria in North America in 1887, where Klebs and Tomassi (1887) commented on the apparent resistance to malaria of those of African descent, who &ldquo;better than any other resist (malaria's) action&rdquo;.",
"   </p>",
"   <p>",
"    However, it was AE Garrod who stated a clear hypothesis that constitutional factors may underlie the striking individual variation in the outcome of infectious disease.",
"   </p>",
"   <p>",
"    Later, support for a contribution of genetic factors to malaria susceptibility came from malaria therapy, when patients with neurosyphilis were deliberately infected with malaria for treatment purposes; the marked variation in susceptibility observed in non-immune adults was accepted as general evidence for a genetic contribution.",
"   </p>",
"   <p>",
"    However, the first clues about some of the genes that might contribute to malaria protection were provided by population genetic studies. A number of genes, including those for sickle hemoglobin (Hb S), the thalassemias, and a range of red cell membrane and enzyme abnormalities, share a distribution that is strikingly similar to that of malaria. It has now been confirmed that many of these traits provide substantial protection against the disease.",
"   </p>",
"   <p>",
"    Intriguingly, most of these red cell genetic defects in human populations have been selected during the last 3000 to 5000 years with the emergence of agriculture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/11\">",
"     11",
"    </a>",
"    ]. However, other factors also affect the outcome of individual malaria infections including previous exposure and immune status and determinants of parasite virulence.",
"   </p>",
"   <p>",
"    Mackinnon and colleagues (2000) have examined pedigree data collected during longitudinal cohort studies in Sri Lanka [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/12\">",
"     12",
"    </a>",
"    ] and calculated 20 percent of the variation in the intensity of disease was explained by repeatable differences between patients, and approximately half of this variation was attributable to host genetics. A similar analysis of the total genetic contribution to malaria infection and disease in Africa showed 25 percent of the total variation in the incidence of hospital admission for malaria was related was explained by additively acting host genes. Interestingly, only 2 percent of this variation was due to the sickle cell trait, suggesting that the additive effect of the many other, largely undefined genetic resistance traits is much greater than those at the globin loci [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A series of case control and some cohort studies have explored the role of specific hemoglobinopathies in resistance to malaria. A meta-analysis of these case control studies showed a decreased risk of severe P.&nbsp;falciparum&nbsp;malaria&nbsp;in individuals with hemoglobin AS (OR 0.09, 95% CI 0.06-0.12), hemoglobin CC (0.27, 0.11-0.63), hemoglobin AC (0.83, 0.67-0.96), homozygous &alpha;-thalassemia&nbsp;(0.63, 0.48-0.83), and heterozygous &alpha;-thalassemia&nbsp;(0.83, 0.74-0.92). However, only hemoglobin AS showed protection from uncomplicated&nbsp;malaria&nbsp;(IRR 0.69, 95% CI 0.61-0.79), while no hemoglobinopathies&nbsp;led to consistent protection from asymptomatic parasitaemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FALCIPARUM MALARIA AND HEMOGLOBIN S",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early observations suggested that the peculiar distribution of sickle cell trait in African populations might result from a selective advantage against malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, the &ldquo;malaria hypothesis&rdquo; is generally ascribed to Haldane (1949) who, reflecting on the evolving descriptions of the global distribution of beta thalassemia, wrote:",
"   </p>",
"   <p>",
"    &ldquo;The corpuscles of the anaemic heterozygotes are smaller than normal, and more resistant to hypotonic solutions. It is at least conceivable that they are also more resistant to attacks by the sporozoa which cause malaria, a disease prevalent in Italy, Sicily and Greece, where the gene is frequent&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since Haldane's first statement of his &ldquo;malaria hypothesis&rdquo;, evidence that many genes provide protection from P. falciparum malaria has accumulated relentlessly. However, transmission experiments have suggested that the &ldquo;protective hemoglobin variants&rdquo; (eg, hemoglobins S, and C) may be associated with an increase in parasite transmission from the human host to the Anopheles mosquito vector [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sickle cell trait",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Epidemiological evidence for protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin S is a variant form of hemoglobin due to an abnormal beta globin chain. Homozygotes for this mutation (Hb SS) suffer from sickle cell disease, a debilitating form of anemia associated with premature death in most developing countries. Nevertheless, it became increasingly obvious that the carrier state (sickle cell trait, Hb AS) was extremely common in much of sub-Saharan Africa. Support for this hypothesis of a balanced polymorphism was shown through the observation that sickle cell heterozygotes (Hb AS) were less likely to have parasites in their blood and were less likely to die from severe malaria than normal subjects (Hb AA) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=see_link\">",
"     \"Sickle cell trait\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Case control studies have since confirmed that sickle cell trait is 90 percent protective against severe and complicated malaria (cerebral malaria and severe anemia) and 60 percent protective against clinical malaria leading to hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. A cohort study has shown that sickle trait confers 60 percent protection against mortality between 2 and 16 months of age in an area of high transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/10\">",
"     10",
"    </a>",
"    ]. Although there is some evidence for protection against mild clinical malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/21-23\">",
"     21-23",
"    </a>",
"    ], this is generally manifest as reduced parasite densities rather than protection against parasitemia per se.",
"   </p>",
"   <p>",
"    Malaria infection strongly predisposes to bacteremia, often with non-salmonella typhi species. In malaria endemic areas, Hb AS may protect not only from malaria but also from bacteremia (odds ratio 0.36; 95% CI 0.2-0.65) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most comprehensive longitudinal studies of the role of sickle cell trait in protection from malaria have shown protection from mild disease and from severe disease but negative epistasis (or interaction) between the malaria-protective effects of alpha-thalassemia and sickle cell trait. The protection afforded by each condition inherited alone was lost when the two conditions were inherited together, to such a degree that the incidence of both uncomplicated and severe P. falciparum malaria was close to baseline in children with both Hb AS and homozygosity for alpha(+) thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, clinical epidemiology has yielded few clues regarding the mechanisms involved in this protection. While an early report showed a reduced parasite prevalence in heterozygotes (Hb AS) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/19\">",
"     19",
"    </a>",
"    ], subsequent surveys have not produced consistent evidence for protection against asymptomatic parasitemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms by which sickle cell trait protects against P. falciparum are not fully understood, and may be both innate and acquired [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, two principal factors are increased sickling and impaired growth of the parasite during vascular sequestration.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased sickling &mdash; Studies using cultured parasitized sickle cell trait red cells at physiologic levels of deoxygenation showed that cells infected with ring forms had accelerated sickling compared with noninfected cells [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. Accelerated sickling might be beneficial by promoting removal of infected cells from the circulation, a phenomenon that has been called \"suicidal\" infection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/29\">",
"       29",
"      </a>",
"      ]. However, morphologic sickling did not occur in sickle cell trait cells containing trophozoites (which do not circulate since they are sequestered in the microcirculation), although abundant Hb S polymer was detectable by electron microscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Impaired parasite growth &mdash; P. falciparum grows normally in infected sickle cell trait cells exposed to 17 percent oxygen, but reducing the oxygen content to 3 percent results in parasite death within a few days [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/30\">",
"       30",
"      </a>",
"      ]. This deoxygenation effect is more pronounced in Hb SC and Hb SS erythrocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even if infected sickle cells do not undergo morphologic sickling, the parasites are still hampered in the early trophozoite stage. P. falciparum growth is impaired in deoxygenated sickle trait cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/31-33\">",
"     31-33",
"    </a>",
"    ], although the rate of parasite invasion appears to be intact [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/33\">",
"     33",
"    </a>",
"    ]. Reduction in growth has been ascribed to dysregulated microRNA (miRNA) in HbAS or HbSS erythrocytes. A subset of erythrocyte miRNAs translocates into the parasite and reduces the growth of the parasites by integration of miR-451 and let-7i into essential parasite mRNAs and so inhibition of translation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrastructural studies of parasitized sickle cell anemia cells have shown that, after six hours of deoxygenation, there is disruption of the parasitic vacuole and other membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/35\">",
"     35",
"    </a>",
"    ]. This membrane disruption in sickle cell trait erythrocytes may be due to puncture by spear-like polymers, which might account for the cell lysis observed with parasitized erythrocytes in sickle cell anemia. Another possibility is that the Hb S polymer, with its considerably right shifted oxygen equilibrium curve, kills the parasite by oxygen toxicity as it releases oxygen during the process of polymerization.",
"   </p>",
"   <p>",
"    Two mechanisms, which are not mutually exclusive, have been proposed to explain impaired parasite growth or death in deoxygenated sickle trait erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The loss of potassium that accompanies sickling could be detrimental to parasite growth. Sickle erythrocytes have two abnormal mechanisms that facilitate potassium loss. One is the increased activity of the K-Cl cotransporter, due in part to absence of the normal inhibition of the transporter by low oxygen tension, along with retention of its ability to be activated by low pH; both of which occur at sites of stagnant circulation. The second mechanism is increased activity of the calcium-dependent (Gardos) potassium channel, due to a transient increase in cell calcium during sickling [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/37-39\">",
"       37-39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H17#H17\">",
"       \"Specific therapies for sickle cell disease\", section on 'Mechanism of erythrocyte dehydration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The osmotic loss of water that follows the loss of potassium increases the mean cell Hb S concentration and Hb S polymerization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=see_link\">",
"       \"Sickle hemoglobin polymer: Structure and functional properties\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parasite growth is normal in red cells that have a low potassium concentration induced by incubation with ouabain, which inhibits the Na-K-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. This observation suggests that water loss with promotion of polymerization of Hb S, not a low potassium content, is of primary importance for impairment in parasite growth.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased phagocytosis &mdash; Malaria-infected erythrocytes containing Hb AS are susceptible to enhanced phagocytosis of ring forms of the parasite. Enhanced phagocytosis of ring or the early intraerythrocytic form of the parasite may also be an explanation for protection in G6PD deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Membrane-bound hemichromes, autologous immunoglobulin G (IgG) and complement C3c fragments, aggregated band 3, and phagocytosis by human monocytes were greater in rings developing in Hb AS erythrocytes than in controls, and phagocytosis of ring-parasitized Hb AS erythrocytes was predominantly complement mediated. Similar findings were reported for red cells in beta-thalassemia trait and Hb H disease, but not for alpha-thalassemia trait erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also evidence for altered actin polymerization in malaria-infected Hb AS cells. Hemoglobins S and C affect the trafficking system that directs parasite-encoded proteins to the surface of infected erythrocytes. Hemoglobin oxidation may inhibit actin polymerization and disrupt the actin cytoskeleton and Maurer&rsquo;s clefts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/43\">",
"     43",
"    </a>",
"    ]. Maurer's clefts moved significantly faster in infected erythrocytes containing the hemoglobin variants S and C than in infected wild-type erythrocytes due to an impaired actin network in infected erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced cytoadherence &mdash; Infected red blood cells from sickle trait individuals (Hb AS) demonstrate reduced in vitro adhesion to microvascular endothelial cells and blood monocytes relative to adhesion of infected Hb AA red blood cells. Hb AS red cells also show reduced expression on their surface of the variant antigen PfEMP-1 (Plasmodium falciparum erythrocyte membrane protein-1), the parasite's major cytoadherence ligand and virulence factor [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/45\">",
"       45",
"      </a>",
"      ]. However, the significance of this phenomenon in patients with malaria is unclear, as increased phagocytosis of ring stage-infected red blood cells, occurring before the production of an adhesive phenotype mediated by expression of Pf-EMP-1, may be more significant in vivo.",
"     </li>",
"     <li>",
"      Immune mechanisms &mdash; A series of intriguing observations suggests that the protection of people with sickle cell trait may be mediated, at least in part, by enhancing the acquired immune response to malaria [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/46-48\">",
"       46-48",
"      </a>",
"      ]. Such an explicit immune-mediated mechanism(s) would explain observations that the effect of AS on parasite density was strongly age-dependent, only beginning after two years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two studies have found significantly raised gamma globulin levels in young Hb AS children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. More specifically, children with the Hb AS phenotype had higher levels of anti-sporozoite antibodies and agglutinating antibodies to variant surface antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/22\">",
"     22",
"    </a>",
"    ] and significantly increased lymphoproliferative responses to malaria antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/51\">",
"     51",
"    </a>",
"    ]. However, the antibody response against a microarray of P. falciparum proteins showed no significant difference in antibody responses in children with Hb AS and Hb AA controls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/52\">",
"     52",
"    </a>",
"    ]. It remains possible that Hb AS and Hb AC may modulate other protective immune responses.",
"   </p>",
"   <p>",
"    There is some direct epidemiological data suggesting that protection mediated by sickle hemoglobin may involve the accelerated acquisition of malaria-specific immunity. The age-specific protection afforded by Hb AS against clinical malaria in children living on the coast of Kenya increased from 20 percent in the first two years of life to a maximum of 56 percent by the age of 10 years, returning to 30 percent in children more than 10 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no equivalent data for the other hemoglobinopathies; a small study in Gambian children with thalassemia trait showed no differences in their immune responses to malaria compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of an enhanced immunological response has not been established either in vitro or by ex vivo clinical studies. While infected variant erythrocytes may be able to stimulate immune responses, early clearance of infected erythrocytes at the ring stage of development may prevent immune responses against malaria parasites by a number of mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Removal of ring stage parasites would reduce production of malaria pigment formed by the digestion of hemoglobin in the host erythrocytes and subsequent dysregulation of monocyte function [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Removal of ring stage parasites would reduce adhesion of infected erythrocytes to myeloid dendritic cell and macrophages, decreasing down-regulation of innate and acquired immune responses [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/56,57\">",
"       56,57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mouse models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mice are susceptible to several species of Plasmodia and a transgenic mouse model expressing sickle cell disease has allowed new approaches to dissecting the protective mechanisms of malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/7,58-60\">",
"     7,58-60",
"    </a>",
"    ]. In studies of sickle transgenic mice, P. chabaudi adami, P. berghei, and the P. yoelii strains were used in nonlethal and lethal infections. In these studies, a transgenic mouse line expressing both the sickle gene and human alpha globin genes was used. To increase the relative expression of sickle globin, the transgenic mice were bred to homozygosity for an alpha thalassemia mutation, resulting in an animal model intermediate in severity between sickle cell trait and sickle cell anemia.",
"   </p>",
"   <p>",
"    When these mice were infected with two species of rodent malaria, they showed a diminished and delayed increase in parasitemia compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/7\">",
"     7",
"    </a>",
"    ]. This benefit in P. chabaudi adami infection was completely prevented by splenectomy, suggesting that \"suicidal\" infection, in which the infected red cells were removed by the spleen, is of primary importance.",
"   </p>",
"   <p>",
"    As in humans, the protection afforded by Hb S is dose-dependent in transgenic mice. This was illustrated in a study that evaluated the response of three transgenic models, expressing 39, 57, and 75 percent Hb S, to challenge with a virulent strain of P. yoelii that is lethal and appears to cause cerebral malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/61\">",
"     61",
"    </a>",
"    ]. Protection was in direct proportion to the level of expression of the sickle gene:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low expressors (39 percent HbS) and controls (no Hb S) rapidly succumbed to the infection.",
"     </li>",
"     <li>",
"      Seven of nine intermediate expressors (57 percent Hb S) initially survived, but all died at day six.",
"     </li>",
"     <li>",
"      The majority of high expressors (75 percent Hb S) survived; those who ultimately died survived up to 16 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among mice in the last two groups, malarial parasites were found almost exclusively in reticulocytes, suggesting that there is greater resistance to malarial infection in mature erythrocytes expressing Hb S.",
"   </p>",
"   <p>",
"    There is also evidence for modulation of the innate immune response to malaria. One murine model of sickle cell anemia with significant steady state hemolysis has shown that these mice are resistant to experimental cerebral malaria (ECM). This protective effect was attributed to induction of heme oxygenase-1 (HO-1) in hematopoietic cells, via a mechanism involving the transcription factor NF-E2-related factor 2 (Nrf2) and generation of carbon monoxide (CO) as a byproduct of heme catabolism by HO-1. This prevented further accumulation of circulating free heme, activation of the immune response, and activation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    expansion of pathogenic CD8(+) T cells. It is unclear if these mechanisms are present in human infections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is widely believed that malaria is a major risk factor for death among children with sickle cell disease (SCD), although there is no clear evidence that children with SCD are at greater risk from malaria than children without SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Children with Hb SS are no more likely to have uncomplicated malaria or malaria complicated by a range of well-described clinical features of severity than controls. Nevertheless, mortality was considerably higher among children with Hb SS than controls with Hb AA or Hb AS children hospitalized with malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results were reported from Tanzania, where parasitemia during the hospitalization of children with SCD was associated with both severe anemia and death [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/66\">",
"     66",
"    </a>",
"    ]. Indeed, intermittent preventive treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"     sulfadoxine-pyrimethamine",
"    </a>",
"    in patients with Hb SS may significantly reduce patients' complaints and blood requirements, but not vaso-occlusive crises and hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;People with sickle cell trait are partially protected from death caused by P. falciparum malaria through several possible mechanisms. The first line of defense is a dramatic acceleration of sickling rates in parasitized sickle cell trait cells that facilitates their removal from the circulation. Parasites that escape this process show impaired growth when the host cells become hypoxic and adhere to the endothelium of venules. Second, ring-stage infected red blood cells from people with Hb AS undergo increased phagocytosis compared with infected red blood cells from people with Hb AA. These effects may lead to an accelerated acquisition of immunity to malaria. It is unclear if any of these mechanism(s) is significant in vivo.",
"   </p>",
"   <p>",
"    It has been generally thought that people with sickle cell anemia (Hb SS) remain susceptible to malaria, although the relative risk of malaria in Africans with sickle cell anemia has not been established. While patients with sickle cell anemia may be less likely to die from cerebral or hepatic malaria, they may succumb to other effects of infection (eg, volume depletion, acidosis, cytokine release).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HEMOGLOBIN C",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemoglobin C (Hb C) gene has its maximum frequency in northern Burkina Faso (formerly called Upper Volta) and the prevalence decreases concentrically in surrounding areas. A case control study involving 4348 Mossi subjects from Burkina Faso suggests a 29 and 93 percent reduction in risk of clinical malaria in Hb C heterozygotes (Hb AC) and homozygotes (Hb CC), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mechanisms of protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies in oxygenated Hb CC cells have shown the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No abnormality in parasite invasion.",
"     </li>",
"     <li>",
"      Normal growth during the first growth cycle but a markedly reduced number of ring forms following the schizont stage, with degenerated schizonts observed on day four. This defect was not affected by deoxygenation or an increase in the extracellular potassium concentration, excluding a potassium leak-dependent mechanism.",
"     </li>",
"     <li>",
"      Marked resistance to osmotic lysis compared with parasitized normal cells. Thus, these cells cannot burst and release merozoites in a normal fashion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important observation that remains unexplained is that Hb C trait red cells sustain parasite growth as well as do normal red cells. However, there is good epidemiological evidence that there is a protective effect of the heterozygous (Hb AC) state, especially in regard to cerebral malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It seems likely that Hb C modulates the cell surface properties of P. falciparum-infected erythrocytes by reducing expression of the variant antigen (Pf-EMP-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/70\">",
"     70",
"    </a>",
"    ]. As a result, infected red blood cells with Hb AC or Hb CC show reduced adhesion to endothelial cells expressing CD36 and intercellular adhesion molecule-1 (ICAM-1), reduced rosetting with uninfected red blood cells, and reduced agglutination in the presence of pooled sera from malaria-immune adults. In malaria-infected red blood cells, the presence of hemoglobin C may inhibit actin polymerization and the production of Maurer&rsquo;s clefts, both of which are necessary for directing parasite-encoded proteins to the surface of infected red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data strongly suggest that sequestration of Hb C-containing erythrocytes would be diminished compared with Hb AA-infected red blood cells and thus represent a potent mechanism of protection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HEMOGLOBIN SC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In culture, oxygenated Hb SC cells (ie, red cells from patients who are doubly heterozygous for the presence of hemoglobins S and C) are indistinguishable from normal cells as a host for plasmodia. However, the parasite rapidly dies when Hb SC cells are partially deoxygenated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/71\">",
"     71",
"    </a>",
"    ]. Why this occurs is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mechanisms of protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible mechanisms whereby patients with hemoglobin SC disease might be protected against malaria include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lowering of the intra-erythrocyte pH by parasite metabolism, inducing more deoxy Hb S polymerization in a red cell with high mean corpuscular hemoglobin concentration (MCHC) due to the presence of Hb C.",
"     </li>",
"     <li>",
"      Increased crystallization of Hb C induced by the presence of Hb S, creating an inadequate substrate for the parasite's proteases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is, at least in the United States, little mortality from Hb SC disease before reproductive age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/73\">",
"     73",
"    </a>",
"    ]. Even in the extreme conditions of some parts of sub-Saharan West Africa, it is likely that subjects with Hb SC disease have a significantly higher fitness than normal individuals because of their resistance to malaria. They may also have a higher fitness than subjects with Hb C trait, as demonstrated by the intensity of parasite growth inhibition in vitro.",
"   </p>",
"   <p>",
"    A model of this type would explain the introduction of an additional advantageous hemoglobin gene into a population that already has one or more genes that provide malaria resistance. Combined heterozygotes might compound the mechanisms of resistance, producing a more fit individual in a malarious region.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HEMOGLOBIN E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin E, a mutation of the beta globin chain, which is also associated with reduced expression, is the most frequent hemoglobin structural mutation in Southeast Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/74\">",
"     74",
"    </a>",
"    ]. The highest frequency of this gene is observed in the \"Hb E triangle\" where the frontiers of Cambodia, Laos, and Thailand converge. In the central region of Indochina, red cell genetic defects (eg, Hb E, thalassemia, and glucose-6-phosphate dehydrogenase deficiency) are so common that only about 15 percent of the population has \"normal\" red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=see_link&amp;anchor=H10#H10\">",
"     \"Introduction to hemoglobin mutations\", section on 'Hemoglobin E'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early epidemiological studies suggested a connection between this abnormal hemoglobin and malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/74\">",
"     74",
"    </a>",
"    ]. In addition, in a report of Southeast Asian refugees, carriers of Hb E (both disease and trait) had significantly higher levels of antimalarial antibodies than individuals with Hb AA from the same geographic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While there is no direct evidence for the protective effect of Hb E in malaria, the pattern of linkage disequilibrium surrounding the beta globin locus in Thailand suggests a single origin of Hb E arising between 1200 to 4400 years ago and a rapid increase in allelic frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mechanisms of protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial in vitro studies of the relationship between P. falciparum and Hb E-containing cells demonstrated a moderate decrease in growth of P. falciparum in Hb E disease cells but not Hb E trait cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/78\">",
"     78",
"    </a>",
"    ]. A subsequent report showed diminished growth of parasites in both Hb E trait and Hb E disease cells that was most pronounced as the concentration of Hb E increased; this effect was maximal at 20 percent oxygen and present but decreased at 5 percent oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional studies suggest that red cells from subjects with Hb E trait have a membrane \"difference\" that renders the majority of the red cell population relatively resistant to invasion by P. falciparum, preventing development of heavy parasite burdens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/79\">",
"     79",
"    </a>",
"    ]. In addition, Hb E is somewhat unstable and is capable of generating free radicals and inducing oxidative damage to the red cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/80\">",
"     80",
"    </a>",
"    ]. The oxidant activity of Hb E may explain the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitamin C, an antioxidant, partially inhibits the Hb E-associated reduction in parasite growth in 20 percent oxygen cultures [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Parasitized Hb E disease and Hb E trait erythrocytes are phagocytized to a greater extent by normal human monocytes than infected erythrocytes from normal individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/4\">",
"       4",
"      </a>",
"      ]. This phenomenon is particularly prominent in late trophozoites and schizonts, suggesting that the surface of parasitized Hb E-containing red cells is modified compared with normal red cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     NEONATAL RED CELLS AND HEMOGLOBIN F",
"    </span>",
"    &nbsp;&mdash;&nbsp;The growth of P. falciparum is diminished in red cells containing fetal hemoglobin (Hb F), even though parasite invasion may be increased in umbilical cord red cells, which have a high concentration of Hb F [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Reduced parasite growth appears to be due directly to Hb F, since it can be demonstrated in all red cells containing Hb F. These include cord blood cells containing a majority of Hb F, red cells from infants&rsquo; F cells (which contain about 20 percent Hb F), and red cells from adults homozygous for hereditary persistence of fetal hemoglobin (HPFH), whose red cells contain almost 100 percent Hb F [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mechanisms of protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies suggest that the decrease in parasite growth associated with the presence of Hb F may be mediated by an increase in intraerythrocytic oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/83\">",
"     83",
"    </a>",
"    ]. This mechanism was studied directly in transgenic mice with 40 to 60 percent Hb F [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/84\">",
"     84",
"    </a>",
"    ]. The mice were infected with three types of rodent malaria and the following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In mice infected with P. chabaudi adami, which causes a nonlethal infection mainly in mature red cells, there was a more rapid rise in parasitemia than in control mice, consistent with the findings noted above [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/81,82\">",
"       81,82",
"      </a>",
"      ], but the parasitemia was cleared more rapidly.",
"     </li>",
"     <li>",
"      In mice infected with P. yoelii 17XNL, which induces a nonlethal infection that primarily consists of invasion of reticulocytes, there was a reduction in parasitemia that was not reversed by prior splenectomy. This is different from the importance of the spleen in the protective effect of Hb S, as described above [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The benefit was greatest in mice infected with P. yoelii 17XL, a lethal variant that produces a syndrome resembling cerebral malaria caused by P. falciparum in humans [",
"      <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/85\">",
"       85",
"      </a>",
"      ] and almost invariably causes death in one to two weeks. While control mice died between 11 to 23 days, transgenic mice cleared the infection by day 22 and survived. This effect was not mediated by the spleen, since similar results were seen in splenectomized animals.",
"     </li>",
"     <li>",
"      Light microscopy revealed that intraerythrocytic parasites developed more slowly in Hb F-containing erythrocytes. Hb F was digested only half as well as Hb A by malarial hemoglobinases (recombinant plasmepsin II), which could explain the slowing of parasite growth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, resistance to malaria of normal neonates and infants in the first six months of life can be explained by a double mechanism: increased malaria invasion rates in Hb F-containing cells, resulting in fewer parasites available for invasion of the Hb A-containing cells; and slowed growth within the Hb F cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/82\">",
"     82",
"    </a>",
"    ]. These factors may also contribute to the advantages of being a carrier of thalassemia, since this disorder is associated with a significant slowing of the postnatal switch from Hb F to Hb A. Protection during the first six months of life is critical, since humoral and cellular defenses are not yet effective during this period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     THALASSEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both alpha thalassemia and, to a lesser degree, beta thalassemia are protective against malarial infection, although fewer studies support the selective advantage of thalassemia compared with other red cell polymorphisms.",
"   </p>",
"   <p>",
"    The initial evidence supporting malaria protection by both forms of thalassemia was derived from population genetic studies. Globally, the thalassemias are the most common single gene disorders thus far described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/86\">",
"     86",
"    </a>",
"    ]. Overall, gene frequencies &gt;0.10 are the norm in tropical populations, whereas frequencies are somewhat lower in the subtropics and rare in the temperate zones. Moreover, isolated examples of extreme frequencies have been described in particular ethnic groups, particularly in certain tribes in India and Nepal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/87-90\">",
"     87-90",
"    </a>",
"    ]. In one of these tribal groups, the Tharu people of Nepal, the alpha thalassemia gene frequency reaches 0.78 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the global distribution of the thalassemias provides reasonable evidence for malaria protection, the probability that malaria was responsible for this selection was further supported by micro-epidemiological data from Italy and the Pacific. In a series of classic studies conducted in the 1960s, a cline (or gradient) in the population frequencies of beta thalassemia in Sardinia correlated with altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/92\">",
"     92",
"    </a>",
"    ]. Although malaria was no longer endemic in Sardinia when these studies were conducted, historically, the incidence of malaria was known to have correlated closely with altitude. The favored hypothesis was that the cline represented selection for the thalassemic beta globin gene under pressure from malaria.",
"   </p>",
"   <p>",
"    Support for this hypothesis has since come from the Pacific. While the gene frequency for beta thalassemia followed a similar correlation with altitude in Papua New Guinea [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/93\">",
"     93",
"    </a>",
"    ], it was the data for alpha thalassemia collected from communities throughout Melanesia that was perhaps the more dramatic. These data showed that alpha thalassemia was found in all malaria-exposed populations and at gene frequencies that were proportional to the incidence of malaria based on historical reports.",
"   </p>",
"   <p>",
"    A cline in the alpha thalassemia haplotype frequency was seen both from north to south and with increasing altitude, each of which are paralleled by a cline in the historical incidence of malaria. In addition, the genetic deletions responsible were numerous and regionally specific. Further, population frequencies of other &ldquo;neutral&rdquo; genetic markers, including the gamma globin haplotypes, showed no such correlation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. A similar conclusion was reached in a study of children resident in 13 villages in the Eastern Arc Mountains in Tanzania, where Plasmodium falciparum transmission intensity is closely correlated with altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations provide some of the strongest circumstantial evidence for malaria protection by the thalassemias. Additional direct evidence for a protective effect of the thalassemia traits is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Oxidant injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that, in the thalassemias (ie, alpha and beta thalassemia, Hb E and Hb Constant Spring), oxidant injury is a prominent factor in parasitized thalassemic red cells and contributes to the protection against severe malarial infection. Parasitized red cells are under substantial oxidant challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/97\">",
"     97",
"    </a>",
"    ], an effect that may be enhanced by the release of superoxide anions by effector T-cells upon binding to infected red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. In addition, the red cell membrane in thalassemic cells undergoes oxidative damage initiated by the binding of excess globin chains, mostly in the form of hemichromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link\">",
"     \"Pathophysiology of beta thalassemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=see_link\">",
"     \"Pathophysiology of alpha thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of intrinsic thalassemic injury and the effect of malarial infection produces a red cell with less viability. These changes permit the preferential destruction and removal of thalassemic parasitized red cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Beta thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential protective effect of beta thalassemia trait was illustrated in a population survey in Northern Liberia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/20\">",
"     20",
"    </a>",
"    ]. There was an increasing frequency of thalassemia trait with increasing age, suggesting that carriers had increased survival. Although P. falciparum prevalence rates were similar in normal and beta thalassemia trait children, the latter group had lower parasite densities. Using a parasite density of &ge;1 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    to indicate a potentially lethal infection, the relative risk was 0.45 in children between the ages of one and four with beta thalassemia trait when compared with those without thalassemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Mechanisms of protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both diminished parasite growth and altered function of infected red blood cells may contribute to the protection against malaria in beta thalassemia. In initially-performed culture studies, parasites grew normally in thalassemia trait red cells, but parasites were more susceptible to oxidants than were parasites growing in normal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/83\">",
"     83",
"    </a>",
"    ]. However, the inability to demonstrate impaired parasite growth in this and other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/100\">",
"     100",
"    </a>",
"    ] may have been due to the use of culture media with an abundance of amino acids essential for parasite growth that are usually obtained by the digestion of hemoglobin by malarial hemoglobinases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/101\">",
"     101",
"    </a>",
"    ]. Such an abundance of amino acids in the culture media would mask the limitations encountered by the parasite in the hypochromic (ie, hemoglobin deficient) red cells of subjects with thalassemia.",
"   </p>",
"   <p>",
"    The impairment in parasite growth that has been demonstrated in other studies varies with the type of thalassemic erythrocyte. This impairment is less prominent in heterozygotes with beta thalassemia than in alpha thalassemia, the alpha thalassemia variant Hb",
"    <span class=\"nowrap\">",
"     H/Constant",
"    </span>",
"    Spring, or combined beta",
"    <span class=\"nowrap\">",
"     thalassemia/Hb",
"    </span>",
"    E [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/101,102\">",
"     101,102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms involved in diminished parasite growth in beta thalassemic cells are not well understood, but persistence of Hb F plays a contributory role in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/81,82\">",
"     81,82",
"    </a>",
"    ] In addition, oxidant injury may promote the preferential removal of parasitized thalassemic red cells (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Oxidant injury'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Transgenic mice have contributed to our understanding of the relationship between beta thalassemia and malaria. Beta thalassemic mice have lower and delayed peak parasitemia after infection with P. chabaudi adami, which has no preference for immature red cells, but not with P. berghei, which preferentially invades reticulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/103\">",
"     103",
"    </a>",
"    ]. The protective effect against P. chabaudi adami was reversed by transgenic correction with the normal human beta globin gene.",
"   </p>",
"   <p>",
"    In addition to reduced parasite growth, beta thalassemic erythrocytes infected with P. falciparum show marked reductions in the tendency to cytoadhere and to form rosettes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/104\">",
"     104",
"    </a>",
"    ]. These abnormalities are associated with diminished expression of parasite antigens on the surface of infected thalassemic red cells in the trophozoite or schizont stage, but not in the ring form stage.",
"   </p>",
"   <p>",
"    Malaria-infected erythrocytes from people with beta thalassemia trait are susceptible to enhanced phagocytosis of ring forms of the parasite. Membrane-bound hemichromes, autologous immunoglobulin G (IgG) and complement C3c fragments, aggregated band 3, and phagocytosis by human monocytes were increased in ring forms of the parasite developing in beta thalassemia trait erythrocytes compared with control infected erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/6\">",
"     6",
"    </a>",
"    ]. Enhanced phagocytosis of ring-parasitized mutant RBCs may represent the common mechanism for malaria protection in nonimmune individuals affected by beta globin variants, while individuals with alpha thalassemia trait are likely protected by a different mechanism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Alpha thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall distribution of alpha thalassemia in malaria endemic areas may be explained by negative epistasis with sickle cell trait. Thus, while both sickle cell trait and alpha thalassemia offer protection against malaria, this protective effect is lost when alpha thalassemia and sickle cell anemia are co-inherited. This phenomenon could explain the failure of alpha thalassemia to reach fixation in any population in sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/25\">",
"     25",
"    </a>",
"    ], as well as why the sickle cell gene is uncommon in the Mediterranean, where the genes for thalassemia are common [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two studies, one from the South Pacific [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/106\">",
"     106",
"    </a>",
"    ], and the other two from Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/25,107\">",
"     25,107",
"    </a>",
"    ], the relative risk of severe malaria was significantly reduced in carriers of alpha thalassemia trait. In PNG, compared with controls, the risk of severe malaria was 0.40 (95% CI, 0.22-0.74) in alpha thalassemia homozygotes and 0.66 (95% CI, 0.37-1.20) in heterozygotes. Moreover, the risk of hospital admission with infections other than malaria was reduced to a similar degree in homozygous (0.36; 95% CI, 0.22-0.60) and heterozygous (0.63; 95% CI, 0.38-1.07) children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ghanaian children with alpha thalassemia were protected from severe malaria; heterozygous alpha thalassemia was observed in 32.6 percent of controls but in only 26.2 percent of cases (odds ratio [OR], 0.74; 95% CI, 0.56-0.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/107\">",
"     107",
"    </a>",
"    ]. In Kenya, the prevalence of both heterozygous and homozygous alpha thalassemia was reduced in patients with severe malaria compared with controls (adjusted odds ratios 0.73 and 0.57; 95% CIs, 0.57-0.94 and 0.40-0.81) respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small study focusing on mild malaria has shown that alpha thalassemia is associated with a reduced risk of uncomplicated malaria episodes in children in northeastern Tanzania [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/109\">",
"     109",
"    </a>",
"    ]. This advantageous effect seemed to be more predominant in children &gt;5 years of age, although large longitudinal studies are required to derive reliable data on the protection for any genetic trait with age.",
"   </p>",
"   <p>",
"    Large scale detailed studies of the effect of alpha thalassemia on specific syndromes of severe malaria have suggested a potential mechanism of protection. No associations were found between alpha thalassemia and the prevalence of symptomless P. falciparum parasitaemia, the incidence of mild malaria, or parasite densities during malaria episodes. However, the presence of alpha thalassemia showed protection from severe malarial anemia and severe nonmalarial anemia. The incidence rate ratios for alpha thalassemia heterozygotes and homozygotes combined compared with normal children were 0.33 (95% CI 0.15-0.73) for severe malaria anemia and 0.26 (95% CI 0.09-0.77) for severe nonmalarial anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Mechanisms of protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protection against severe malaria associated with alpha thalassemia may be mediated in part by increased susceptibility to infection with the nonlethal P. vivax, particularly in young children, thereby inducing limited cross-species protection against subsequent severe P. falciparum infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/102,111,112\">",
"     102,111,112",
"    </a>",
"    ]. This possibility was illustrated in a study of the epidemiology of malaria in Vanuatu in the northeast Pacific [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/112\">",
"     112",
"    </a>",
"    ]. The prevalence of uncomplicated malaria (P. falciparum and P. vivax) and of splenomegaly (commonly associated with malaria infection) was increased among children under the age of five years with alpha thalassemia; this was not seen in older children.",
"   </p>",
"   <p>",
"    Culture studies suggest impaired P. falciparum growth within infected cells from patients with alpha thalassemia or the alpha thalassemia variants Hb H and Hb Constant Spring [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/5,101,102,113\">",
"     5,101,102,113",
"    </a>",
"    ]. This inhibitory effect was seen only in severe alpha thalassemia (ie, those missing three of the four normal alpha chain genes), and not in those missing only one or two alpha globin genes, and was independent of the presence of Hb F [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/113\">",
"     113",
"    </a>",
"    ]. Another contributing factor in Hb H and Hb Constant Spring may be increased phagocytosis of infected red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/5\">",
"     5",
"    </a>",
"    ]. Such an extrinsic mechanism cannot be detected in culture.",
"   </p>",
"   <p>",
"    Reduced expression of red cell complement receptor 1 (CR1), responsible for red cell rosetting of infected and non-infected red cells, has been associated with alpha thalassemia and may confer protection against severe malaria via this mechanism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39959?source=see_link\">",
"     \"Pathogenesis of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infected red cells from people with &alpha;-thalassemia&nbsp;appear to have reduced expression of the variant antigen PfEMP-1 and subsequently reduced adherence of infected red blood cells (RBCs) to microvascular endothelial cells (MVECs) and monocytes in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/114\">",
"     114",
"    </a>",
"    ]. Such a mechanism may reduce sequestration and the progression to severe disease.",
"   </p>",
"   <p>",
"    Some of the protective effect of homozygous alpha thalassemia on severe anemia may be explained by the increased erythrocyte count and microcytosis, allowing a greater reduction in erythrocyte count than children of normal genotype during malaria infection before the hemoglobin level falls to cause severe anemia (eg, total hemoglobin concentration &lt;5",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/23/20858/abstract/115,116\">",
"     115,116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14230701\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of human genes share a distribution that is strikingly similar to that of malaria. It has now been confirmed that many of these traits provide substantial protection against the disease. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Malaria protection and inherited factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following hemoglobinopathies have been shown to be protective of malarial infection:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin S (sickle cell hemoglobin) (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Falciparum malaria and hemoglobin S'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hemoglobin C (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Hemoglobin C'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hemoglobin SC disease. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hemoglobin SC disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemoglobin E (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Hemoglobin E'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hemoglobin F (fetal hemoglobin) (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Neonatal red cells and hemoglobin F'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Alpha and beta thalassemias (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Thalassemia'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A wide variety of potential mechanisms of protection for hemoglobinopathies against malaria continue to be described, but it is not clear which of these are important in vivo.",
"   </p>",
"   <p>",
"    Inherited abnormalities of red blood cell surface antigens and cytoskeletal proteins, which may also protect against malarial infection, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=see_link\">",
"     \"Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/1\">",
"      Hill AV, Allsopp CE, Kwiatkowski D, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991; 352:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/2\">",
"      Hill AV, Elvin J, Willis AC, et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992; 360:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/3\">",
"      Tiffert T, Lew VL, Ginsburg H, et al. The hydration state of human red blood cells and their susceptibility to invasion by Plasmodium falciparum. Blood 2005; 105:4853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/4\">",
"      Bunyaratvej A, Butthep P, Yuthavong Y, et al. Increased phagocytosis of Plasmodium falciparum-infected erythrocytes with haemoglobin E by peripheral blood monocytes. Acta Haematol 1986; 76:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/5\">",
"      Yuthavong Y, Butthep P, Bunyaratvej A, et al. Impaired parasite growth and increased susceptibility to phagocytosis of Plasmodium falciparum infected alpha-thalassemia or hemoglobin Constant Spring red blood cells. Am J Clin Pathol 1988; 89:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/6\">",
"      Ayi K, Turrini F, Piga A, Arese P. Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait. Blood 2004; 104:3364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/7\">",
"      Shear HL, Roth EF Jr, Fabry ME, et al. Transgenic mice expressing human sickle hemoglobin are partially resistant to rodent malaria. Blood 1993; 81:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/8\">",
"      Flint J, Harding RM, Clegg JB, Boyce AJ. Why are some genetic diseases common? Distinguishing selection from other processes by molecular analysis of globin gene variants. Hum Genet 1993; 91:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/9\">",
"      May J, Evans JA, Timmann C, et al. Hemoglobin variants and disease manifestations in severe falciparum malaria. JAMA 2007; 297:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/10\">",
"      Aidoo M, Terlouw DJ, Kolczak MS, et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 2002; 359:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/11\">",
"      Wiesenfeld SL. Sickle-cell trait in human biological and cultural evolution. Development of agriculture causing increased malaria is bound to gene-pool changes causing malaria reduction. Science 1967; 157:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/12\">",
"      Mackinnon MJ, Gunawardena DM, Rajakaruna J, et al. Quantifying genetic and nongenetic contributions to malarial infection in a Sri Lankan population. Proc Natl Acad Sci U S A 2000; 97:12661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/13\">",
"      Mackinnon MJ, Mwangi TW, Snow RW, et al. Heritability of malaria in Africa. PLoS Med 2005; 2:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/14\">",
"      Taylor SM, Parobek CM, Fairhurst RM. Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/15\">",
"      BEET EA. Sickle cell disease in the Balovale District of Northern Rhodesia. East Afr Med J 1946; 23:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/16\">",
"      ALLISON AC. POLYMORPHISM AND NATURAL SELECTION IN HUMAN POPULATIONS. Cold Spring Harb Symp Quant Biol 1964; 29:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/17\">",
"      Haldane JB. Disease and Evolution. La Ricerce Scientifica 1949; 19:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/18\">",
"      Gouagna LC, Bancone G, Yao F, et al. Genetic variation in human HBB is associated with Plasmodium falciparum transmission. Nat Genet 2010; 42:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/19\">",
"      ALLISON AC. Protection afforded by sickle-cell trait against subtertian malareal infection. Br Med J 1954; 1:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/20\">",
"      Willcox M, Bj&ouml;rkman A, Brohult J. Falciparum malaria and beta-thalassaemia trait in northern Liberia. Ann Trop Med Parasitol 1983; 77:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/21\">",
"      Fleming AF, Storey J, Molineaux L, et al. Abnormal haemoglobins in the Sudan savanna of Nigeria. I. Prevalence of haemoglobins and relationships between sickle cell trait, malaria and survival. Ann Trop Med Parasitol 1979; 73:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/22\">",
"      Marsh K, Otoo L, Hayes RJ, et al. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg 1989; 83:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/23\">",
"      Jakobsen PH, Riley EM, Allen SJ, et al. Differential antibody response of Gambian donors to soluble Plasmodium falciparum antigens. Trans R Soc Trop Med Hyg 1991; 85:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/24\">",
"      Scott JA, Berkley JA, Mwangi I, et al. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 2011; 378:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/25\">",
"      Williams TN, Mwangi TW, Wambua S, et al. Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait. Nat Genet 2005; 37:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/26\">",
"      Gong L, Maiteki-Sebuguzi C, Rosenthal PJ, et al. Evidence for both innate and acquired mechanisms of protection from Plasmodium falciparum in children with sickle cell trait. Blood 2012; 119:3808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/27\">",
"      Bunn HF. The triumph of good over evil: protection by the sickle gene against malaria. Blood 2013; 121:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/28\">",
"      Roth EF Jr, Friedman M, Ueda Y, et al. Sickling rates of human AS red cells infected in vitro with Plasmodium falciparum malaria. Science 1978; 202:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/29\">",
"      Luzzatto L, Nwachuku-Jarrett ES, Reddy S. Increased sickling of parasitised erythrocytes as mechanism of resistance against malaria in the sickle-cell trait. Lancet 1970; 1:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/30\">",
"      Friedman MJ. Erythrocytic mechanism of sickle cell resistance to malaria. Proc Natl Acad Sci U S A 1978; 75:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/31\">",
"      Pasvol G, Weatherall DJ, Wilson RJ. Cellular mechanism for the protective effect of haemoglobin S against P. falciparum malaria. Nature 1978; 274:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/32\">",
"      Pasvol G. The interaction between sickle haemoglobin and the malarial parasite Plasmodium falciparum. Trans R Soc Trop Med Hyg 1980; 74:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/33\">",
"      Olson JA, Nagel RL. Synchronized cultures of P falciparum in abnormal red cells: the mechanism of the inhibition of growth in HbCC cells. Blood 1986; 67:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/34\">",
"      LaMonte G, Philip N, Reardon J, et al. Translocation of sickle cell erythrocyte microRNAs into Plasmodium falciparum inhibits parasite translation and contributes to malaria resistance. Cell Host Microbe 2012; 12:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/35\">",
"      Friedman MJ. Ultrastructural damage to the malaria parasite in the sickled cell. J Protozool 1979; 26:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/36\">",
"      Friedman MJ, Roth EF, Nagel RL, Trager W. Plasmodium falciparum: physiological interactions with the human sickle cell. Exp Parasitol 1979; 47:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/37\">",
"      Olivieri O, Vitoux D, Galacteros F, et al. Hemoglobin variants and activity of the (K+Cl-) cotransport system in human erythrocytes. Blood 1992; 79:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/38\">",
"      Lew VL, Ortiz OE, Bookchin RM. Stochastic nature and red cell population distribution of the sickling-induced Ca2+ permeability. J Clin Invest 1997; 99:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/39\">",
"      Schwartz RS, Musto S, Fabry ME, Nagel RL. Two distinct pathways mediate the formation of intermediate density cells and hyperdense cells from normal density sickle red blood cells. Blood 1998; 92:4844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/40\">",
"      Ginsburg H, Handeli S, Friedman S, et al. Effects of red blood cell potassium and hypertonicity on the growth of Plasmodium falciparum in culture. Z Parasitenkd 1986; 72:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/41\">",
"      Tanabe K, Izumo A, Kageyama K. Growth of Plasmodium falciparum in sodium-enriched human erythrocytes. Am J Trop Med Hyg 1986; 35:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/42\">",
"      Cappadoro M, Giribaldi G, O'Brien E, et al. Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood 1998; 92:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/43\">",
"      Cyrklaff M, Sanchez CP, Kilian N, et al. Hemoglobins S and C interfere with actin remodeling in Plasmodium falciparum-infected erythrocytes. Science 2011; 334:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/44\">",
"      Kilian N, Dittmer M, Cyrklaff M, et al. Haemoglobin S and C affect the motion of Maurer's clefts in Plasmodium falciparum-infected erythrocytes. Cell Microbiol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/45\">",
"      Cholera R, Brittain NJ, Gillrie MR, et al. Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. Proc Natl Acad Sci U S A 2008; 105:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/46\">",
"      Guggenmoos-Holzmann I, Bienzle U, Luzzatto L. Plasmodium falciparum malaria and human red cells. II. Red cell genetic traits and resistance against malaria. Int J Epidemiol 1981; 10:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/47\">",
"      Bayoumi RA. The sickle-cell trait modifies the intensity and specificity of the immune response against P. falciparum malaria and leads to acquired protective immunity. Med Hypotheses 1987; 22:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/48\">",
"      Bayoumi RA. Does the mechanism of protection from falciparum malaria by red cell genetic disorders involve a switch to a balanced TH1/TH2 cytokine production mode? Med Hypotheses 1997; 48:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/49\">",
"      EDOZIEN JC, BOYO AE, MORLEY DC. The relationship of serum gamma-globulin concentration to malaria and sickling. J Clin Pathol 1960; 13:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/50\">",
"      Cornille-Br&oslash;gger R, Fleming AF, Kagan I, et al. Abnormal haemoglobins in the Sudan savanna of Nigeria. II. Immunological response to malaria in normals and subjects with sickle cell trait. Ann Trop Med Parasitol 1979; 73:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/51\">",
"      Abu-Zeid YA, Abdulhadi NH, Theander TG, et al. Seasonal changes in cell mediated immune responses to soluble Plasmodium falciparum antigens in children with haemoglobin AA and haemoglobin AS. Trans R Soc Trop Med Hyg 1992; 86:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/52\">",
"      Tan X, Traore B, Kayentao K, et al. Hemoglobin S and C heterozygosity enhances neither the magnitude nor breadth of antibody responses to a diverse array of Plasmodium falciparum antigens. J Infect Dis 2011; 204:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/53\">",
"      Williams TN, Mwangi TW, Roberts DJ, et al. An immune basis for malaria protection by the sickle cell trait. PLoS Med 2005; 2:e128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/54\">",
"      Allen SJ, Rowe P, Allsopp CE, et al. A prospective study of the influence of alpha thalassaemia on morbidity from malaria and immune responses to defined Plasmodium falciparum antigens in Gambian children. Trans R Soc Trop Med Hyg 1993; 87:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/55\">",
"      Schwarzer E, Turrini F, Ulliers D, et al. Impairment of macrophage functions after ingestion of Plasmodium falciparum-infected erythrocytes or isolated malarial pigment. J Exp Med 1992; 176:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/56\">",
"      Urban BC, Ferguson DJ, Pain A, et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 1999; 400:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/57\">",
"      McGilvray ID, Serghides L, Kapus A, et al. Nonopsonic monocyte/macrophage phagocytosis of Plasmodium falciparum-parasitized erythrocytes: a role for CD36 in malarial clearance. Blood 2000; 96:3231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/58\">",
"      Fabry ME, Nagel RL, Pachnis A, et al. High expression of human beta S- and alpha-globins in transgenic mice: hemoglobin composition and hematological consequences. Proc Natl Acad Sci U S A 1992; 89:12150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/59\">",
"      Fabry ME, Costantini F, Pachnis A, et al. High expression of human beta S- and alpha-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia. Proc Natl Acad Sci U S A 1992; 89:12155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/60\">",
"      Nagel RL. A knockout of a transgenic mouse--animal models of sickle cell anemia. N Engl J Med 1998; 339:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/61\">",
"      Hood AT, Fabry ME, Costantini F, et al. Protection from lethal malaria in transgenic mice expressing sickle hemoglobin. Blood 1996; 87:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/62\">",
"      Ferreira A, Marguti I, Bechmann I, et al. Sickle hemoglobin confers tolerance to Plasmodium infection. Cell 2011; 145:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/63\">",
"      Serjeant GR. Mortality from sickle cell disease in Africa. BMJ 2005; 330:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/64\">",
"      Diallo D, Tchernia G. Sickle cell disease in Africa. Curr Opin Hematol 2002; 9:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/65\">",
"      McAuley CF, Webb C, Makani J, et al. High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya. Blood 2010; 116:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/66\">",
"      Makani J, Komba AN, Cox SE, et al. Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. Blood 2010; 115:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/67\">",
"      Diop S, Soudr&eacute; F, Seck M, et al. Sickle-cell disease and malaria: evaluation of seasonal intermittent preventive treatment with sulfadoxine-pyrimethamine in Senegalese patients-a randomized placebo-controlled trial. Ann Hematol 2011; 90:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/68\">",
"      Modiano D, Luoni G, Sirima BS, et al. Haemoglobin C protects against clinical Plasmodium falciparum malaria. Nature 2001; 414:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/69\">",
"      Kreuels B, Kreuzberg C, Kobbe R, et al. Differing effects of HbS and HbC traits on uncomplicated falciparum malaria, anemia, and child growth. Blood 2010; 115:4551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/70\">",
"      Fairhurst RM, Baruch DI, Brittain NJ, et al. Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. Nature 2005; 435:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/71\">",
"      Friedman MJ, Roth EF, Nagel RL, Trager W. The role of hemoglobins C, S, and Nbalt in the inhibition of malaria parasite development in vitro. Am J Trop Med Hyg 1979; 28:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/72\">",
"      Lin MJ, Nagel RL, Hirsch RE. Acceleration of hemoglobin C crystallization by hemoglobin S. Blood 1989; 74:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/73\">",
"      Leikin SL, Gallagher D, Kinney TR, et al. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics 1989; 84:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/74\">",
"      Flatz G. Hemoglobin E: distribution and population dynamics. Humangenetik 1967; 3:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/75\">",
"      Sicard D, Lieurzou Y, Lapoumeroulie C, Labie D. High genetic polymorphism of hemoglobin disorders in Laos. Complex phenotypes due to associated thalassemic syndromes. Hum Genet 1979; 50:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/76\">",
"      Vernes AJ, Haynes JD, Tang DB, et al. Decreased growth of Plasmodium falciparum in red cells containing haemoglobin E, a role for oxidative stress, and a sero-epidemiological correlation. Trans R Soc Trop Med Hyg 1986; 80:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/77\">",
"      Ohashi J, Naka I, Patarapotikul J, et al. Extended linkage disequilibrium surrounding the hemoglobin E variant due to malarial selection. Am J Hum Genet 2004; 74:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/78\">",
"      Nagel RL, Raventos-Suarez C, Fabry ME, et al. Impairment of the growth of Plasmodium falciparum in HbEE erythrocytes. J Clin Invest 1981; 68:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/79\">",
"      Chotivanich K, Udomsangpetch R, Pattanapanyasat K, et al. Hemoglobin E: a balanced polymorphism protective against high parasitemias and thus severe P falciparum malaria. Blood 2002; 100:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/80\">",
"      Frischer H, Bowman J. Hemoglobin E, an oxidatively unstable mutation. J Lab Clin Med 1975; 85:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/81\">",
"      Pasvol G, Weatherall DJ, Wilson RJ, et al. Fetal haemoglobin and malaria. Lancet 1976; 1:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/82\">",
"      Pasvol G, Weatherall DJ, Wilson RJ. Effects of foetal haemoglobin on susceptibility of red cells to Plasmodium falciparum. Nature 1977; 270:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/83\">",
"      Friedman MJ. Oxidant damage mediates variant red cell resistance to malaria. Nature 1979; 280:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/84\">",
"      Shear HL, Grinberg L, Gilman J, et al. Transgenic mice expressing human fetal globin are protected from malaria by a novel mechanism. Blood 1998; 92:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/85\">",
"      Kaul DK, Nagel RL, Llena JF, Shear HL. Cerebral malaria in mice: demonstration of cytoadherence of infected red blood cells and microrheologic correlates. Am J Trop Med Hyg 1994; 50:512.",
"     </a>",
"    </li>",
"    <li>",
"     Weatherall DJ, Clegg J. The Thalassaemias, Oxford University Press, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/87\">",
"      Brittenham G, Lozoff B, Harris JW, et al. Thalassemia in southern India. Interaction of genes for beta+-, beta o-, and delta o beta o-thalassemia. Acta Haematol 1980; 63:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/88\">",
"      Kulozik AE, Kar BC, Serjeant GR, et al. The molecular basis of alpha thalassemia in India. Its interaction with the sickle cell gene. Blood 1988; 71:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/89\">",
"      Labie D, Srinivas R, Dunda O, et al. Haplotypes in tribal Indians bearing the sickle gene: evidence for the unicentric origin of the beta S mutation and the unicentric origin of the tribal populations of India. Hum Biol 1989; 61:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/90\">",
"      Modiano G, Morpurgo G, Terrenato L, et al. Protection against malaria morbidity: near-fixation of the alpha-thalassemia gene in a Nepalese population. Am J Hum Genet 1991; 48:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/91\">",
"      Terrenato L, Shrestha S, Dixit KA, et al. Decreased malaria morbidity in the Tharu people compared to sympatric populations in Nepal. Ann Trop Med Parasitol 1988; 82:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/92\">",
"      Siniscalco M, Bernini L, Latte B, Motulski AG. Favism and thalassaemia in Sardinia and their relationship to malaria. Nature 1961; 190:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/93\">",
"      Hill AV, Bowden DK, O'Shaughnessy DF, et al. Beta thalassemia in Melanesia: association with malaria and characterization of a common variant (IVS-1 nt 5 G----C). Blood 1988; 72:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/94\">",
"      Flint J, Hill AV, Bowden DK, et al. High frequencies of alpha-thalassaemia are the result of natural selection by malaria. Nature 1986; 321:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/95\">",
"      Yenchitsomanus P, Summers KM, Board PG, et al. Alpha-thalassemia in Papua New Guinea. Hum Genet 1986; 74:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/96\">",
"      Enevold A, Alifrangis M, Sanchez JJ, et al. Associations between alpha+-thalassemia and Plasmodium falciparum malarial infection in northeastern Tanzania. J Infect Dis 2007; 196:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/97\">",
"      Atamna H, Ginsburg H. The malaria parasite supplies glutathione to its host cell--investigation of glutathione transport and metabolism in human erythrocytes infected with Plasmodium falciparum. Eur J Biochem 1997; 250:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/98\">",
"      Allison AC, Eugui EM. A radical interpretation of immunity to malaria parasites. Lancet 1982; 2:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/99\">",
"      Allison AC, Eugui EM. The role of cell-mediated immune responses in resistance to malaria, with special reference to oxidant stress. Annu Rev Immunol 1983; 1:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/100\">",
"      Roth EF Jr, Raventos-Suarez C, Rinaldi A, Nagel RL. Glucose-6-phosphate dehydrogenase deficiency inhibits in vitro growth of Plasmodium falciparum. Proc Natl Acad Sci U S A 1983; 80:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/101\">",
"      Brockelman CR, Wongsattayanont B, Tan-ariya P, Fucharoen S. Thalassemic erythrocytes inhibit in vitro growth of Plasmodium falciparum. J Clin Microbiol 1987; 25:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/102\">",
"      Pattanapanyasat K, Yongvanitchit K, Tongtawe P, et al. Impairment of Plasmodium falciparum growth in thalassemic red blood cells: further evidence by using biotin labeling and flow cytometry. Blood 1999; 93:3116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/103\">",
"      Roth EF Jr, Shear HL, Costantini F, et al. Malaria in beta-thalassemic mice and the effects of the transgenic human beta-globin gene and splenectomy. J Lab Clin Med 1988; 111:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/104\">",
"      Udomsangpetch R, Sueblinvong T, Pattanapanyasat K, et al. Alteration in cytoadherence and rosetting of Plasmodium falciparum-infected thalassemic red blood cells. Blood 1993; 82:3752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/105\">",
"      Penman BS, Pybus OG, Weatherall DJ, Gupta S. Epistatic interactions between genetic disorders of hemoglobin can explain why the sickle-cell gene is uncommon in the Mediterranean. Proc Natl Acad Sci U S A 2009; 106:21242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/106\">",
"      Allen SJ, O'Donnell A, Alexander ND, et al. alpha+-Thalassemia protects children against disease caused by other infections as well as malaria. Proc Natl Acad Sci U S A 1997; 94:14736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/107\">",
"      Mockenhaupt FP, Ehrhardt S, Gellert S, et al. Alpha(+)-thalassemia protects African children from severe malaria. Blood 2004; 104:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/108\">",
"      Williams TN, Wambua S, Uyoga S, et al. Both heterozygous and homozygous alpha+ thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. Blood 2005; 106:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/109\">",
"      Enevold A, Lusingu JP, Mmbando B, et al. Reduced risk of uncomplicated malaria episodes in children with alpha+-thalassemia in northeastern Tanzania. Am J Trop Med Hyg 2008; 78:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/110\">",
"      Wambua S, Mwangi TW, Kortok M, et al. The effect of alpha+-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya. PLoS Med 2006; 3:e158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/111\">",
"      Clegg JB, Weatherall DJ. Thalassemia and malaria: new insights into an old problem. Proc Assoc Am Physicians 1999; 111:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/112\">",
"      Williams TN, Maitland K, Bennett S, et al. High incidence of malaria in alpha-thalassaemic children. Nature 1996; 383:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/113\">",
"      Ifediba TC, Stern A, Ibrahim A, Rieder RF. Plasmodium falciparum in vitro: diminished growth in hemoglobin H disease erythrocytes. Blood 1985; 65:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/114\">",
"      Krause MA, Diakite SA, Lopera-Mesa TM, et al. &alpha;-Thalassemia impairs the cytoadherence of Plasmodium falciparum-infected erythrocytes. PLoS One 2012; 7:e37214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/115\">",
"      Fowkes FJ, Allen SJ, Allen A, et al. Increased microerythrocyte count in homozygous alpha(+)-thalassaemia contributes to protection against severe malarial anaemia. PLoS Med 2008; 5:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/23/20858/abstract/116\">",
"      Veenemans J, Andang'o PE, Mbugi EV, et al. Alpha+ -thalassemia protects against anemia associated with asymptomatic malaria: evidence from community-based surveys in Tanzania and Kenya. J Infect Dis 2008; 198:401.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7099 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-197.136.42.3-505F0169A0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20858=[""].join("\n");
var outline_f20_23_20858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14230701\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REVIEW OF MALARIAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MALARIA PROTECTION AND INHERITED FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FALCIPARUM MALARIA AND HEMOGLOBIN S",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sickle cell trait",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Epidemiological evidence for protection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mouse models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Conclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HEMOGLOBIN C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mechanisms of protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HEMOGLOBIN SC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mechanisms of protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HEMOGLOBIN E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mechanisms of protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      NEONATAL RED CELLS AND HEMOGLOBIN F",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mechanisms of protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      THALASSEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Oxidant injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Mechanisms of protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Mechanisms of protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14230701\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=related_link\">",
"      Introduction to hemoglobin mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39959?source=related_link\">",
"      Pathogenesis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=related_link\">",
"      Pathophysiology of alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=related_link\">",
"      Pathophysiology of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=related_link\">",
"      Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=related_link\">",
"      Sickle cell trait",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=related_link\">",
"      Sickle hemoglobin polymer: Structure and functional properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_23_20859="Long duration chronic daily headache";
var content_f20_23_20859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chronic daily headaches of long duration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"2\">",
"        Chronic daily headaches of long duration are characterized by headache duration &ge;4 hours a day with headaches occurring &ge;15 days per month for &gt;3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Chronic tension-type headache:",
"        </strong>",
"       </td>",
"       <td>",
"        Bilateral, gradual onset, muscle tenderness common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Transformed migraine:",
"        </strong>",
"       </td>",
"       <td>",
"        Variable location, typically of gradual onset, migraine features present, medication overuse common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         New daily persistent headache:",
"        </strong>",
"       </td>",
"       <td>",
"        Sudden onset, usually bilateral, typically unresponsive to treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Hemicrania continua:",
"        </strong>",
"       </td>",
"       <td>",
"        Strictly unilateral, unremitting without pain-free intervals but with variable intensity, autonomic features ipsilateral to the side of pain, responsive to indomethacin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised HIS criteria. Neurology 1996; 47:871.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20859=[""].join("\n");
var outline_f20_23_20859=null;
var title_f20_23_20860="Allergy causes and symptoms PI";
var content_f20_23_20860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes and symptoms of common allergies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of allergy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Caused by",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Seasonal allergies (also called hay fever)",
"       </td>",
"       <td>",
"        Pollen from trees, grasses, or weeds",
"       </td>",
"       <td rowspan=\"5\">",
"        <ul>",
"         <li>",
"          Stuffy nose, runny nose, or sneezing a lot",
"         </li>",
"         <li>",
"          Itchy or red eyes, sore throat, or itching of the throat or ears",
"         </li>",
"         <li>",
"          Waking up at night or trouble sleeping, which can lead to feeling tired during the day",
"         </li>",
"         <li>",
"          Asthma symptoms (wheezing or noisy breathing, coughing, a tight feeling in the chest, and shortness of breath)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mold spores that grow when the weather is humid, wet, or damp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Indoor allergies",
"       </td>",
"       <td>",
"        Mold spores",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Animals, such as cats and dogs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insects, such as dust mites and cockroaches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insect allergies",
"       </td>",
"       <td>",
"        Stings from honeybees, yellow jackets, hornets and wasps, fire ants",
"       </td>",
"       <td rowspan=\"4\">",
"        <ul>",
"         <li>",
"          Red, hot, skin especially on your face (flushing)",
"         </li>",
"         <li>",
"          Red, raised patches of skin that are very itchy (hives)",
"         </li>",
"         <li>",
"          Swelling of the face, eyelids, mouth, tongue, hands, and feet (angioedema)",
"         </li>",
"         <li>",
"          Asthma symptoms (wheezing or noisy breathing, coughing, a tight feeling in the chest, and shortness of breath)",
"         </li>",
"         <li>",
"          Nausea and vomiting",
"         </li>",
"         <li>",
"          Feeling lightheaded or like you might pass out",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Food allergies",
"       </td>",
"       <td>",
"        Milk and foods that contain milk such as ice cream or butter (called dairy foods); eggs, wheat, soy, peanuts, tree nuts, (such as almonds or cashews); fish, shellfish (such as shrimp or oysters)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medicine allergies",
"       </td>",
"       <td>",
"        Penicillin and related medicines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Latex allergy",
"       </td>",
"       <td>",
"        Gloves and other medical supplies that contain latex; condoms, balloons",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20860=[""].join("\n");
var outline_f20_23_20860=null;
var title_f20_23_20861="AHA recs for exercise and diet counseling";
var content_f20_23_20861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Heart Association (AHA) recommendations for counseling to promote dietary and physical activity changes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cognitive-behavioral strategies for promoting behavior change",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Design interventions to target dietary and physical activity behaviors with specific, proximal goals. (Level of evidence: A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide feedback on progress toward goals. (Level of evidence: A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide strategies for self-monitoring. (Level of evidence: A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Establish a plan for frequency and duration of follow-up contacts (eg, in-person, oral, written, electronic) in accordance with individual needs to assess and reinforce progress toward goal achievement. (Level of evidence: A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Utilize motivational interviewing strategies, particularly when an individual is resistant or ambivalent about dietary and physical activity behavior change. (Level of evidence: A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide for direct or peer-based long-term support and follow-up, such as referral to ongoing community-based programs, to offset the common occurrence of declining adherence that typically begins at 4-6 months in most behavior change programs. (Level of evidence: B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Incorporate strategies to build self-efficacy into the intervention. (Level of evidence: A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Use a combination of 2 of the above strategies (eg, goal setting, feedback, self-monitoring, follow-up, motivational interviewing, self-efficacy) in an intervention. (Level of evidence: A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Class II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Use incentives, modeling, and problem solving strategies. (Level of evidence: B)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\">",
"        Intervention processes and/or delivery strategies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Use individual- or group-based strategies. (Level of evidence: A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Use individual-oriented sessions to assess where the individual is in relation to behavior change, to jointly identify the goals for risk reduction or improved cardiovascular health, and to develop a personalized plan to achieve it. (Level of evidence: A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Use group sessions with cognitive-behavioral strategies to teach skills to modify the diet and develop a physical activity program, to provide role modeling and positive observational learning, and to maximize the benefits of peer support and group problem solving. (Level of evidence: A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        For appropriate target populations, use Internet- and computer-based programs to target dietary and physical activity change; adding a form of electronic-counseling improves outcomes. (Level of evidence: B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Use individualized rather than nonindividualized print- or media-only delivery strategies. (Level of evidence: A)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\">",
"        Addressing cultural and social context variables that influence behavioral change",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Utilize church, community, work, or clinic settings for delivery of interventions. (Level of evidence: B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Use a multiple-component delivery strategy that includes a group component rather than individual-only or group-only approaches. (Level of evidence: A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Use culturally-adapted strategies, including use of peer or lay health advisors to increase trust; tailor health messages and counseling strategies to be sensitive to the cultural beliefs, values, language, literacy, and customs of the target population. (Level of evidence: A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Use problem solving to address barriers to physical activity and dietary change, such as transportation barriers, poor local safety, and lack of access to affordable healthier foods and physical activity. (Level of evidence: B)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PA: physical activity; Class I: evidence of effectiveness; Class II: conflicting evidence; Class IIa: weight of evidence in favor; Level of evidence A: data derived from multiple randomized clinical trials; Level of evidence B: data derived from a single randomized trial or nonrandomized studies; Level of evidence C: expert opinion or case studies.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation 2010; 122:406. Copyright &copy; 2010 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20861=[""].join("\n");
var outline_f20_23_20861=null;
var title_f20_23_20862="Vit D metabolism";
var content_f20_23_20862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Pathways of vitamin D synthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 388px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Metabolic activation of vitamin D to calcitriol and its effects on calcium and phosphate homeostasis. The result is an increase in the serum calcium and phosphate concentrations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20862=[""].join("\n");
var outline_f20_23_20862=null;
var title_f20_23_20863="Chlamydia and atherosclerosis";
var content_f20_23_20863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Possible involvement of Chlamydia pneumoniae in atherogenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 363px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    C. pneumoniae infection results in the activation of circulating monocytes which release cytokines and tissue factors that can ultimately lead to endothelial damage and the development of atherosclerosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_23_20863=[""].join("\n");
var outline_f20_23_20863=null;
        